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INTRODUCTION 
Coronary artery disease (CAD) has become a major public health problem in many 
developing countries1,2. CAD is a multifactorial disease caused by genetic and environmental 
factors 3. Lipoproteins play a central role in the development of atherosclerotic cardiovascular 
disease in humans. The protective role of high density lipoprotein cholesterol (HDL-C) 
against atherosclerosis is well established6,7. Numerous genetic, hormonal and environmental 
factors determine HDL-C levels within distinct populations. HDL exerts its cardioprotective 
function through a process called reverse cholesterol transport, in addition to anti-
inflammatory and antioxidative effects. Reverse cholesterol transport describes a metabolic 
pathway initiated by HDL-mediated efflux from peripheral tissues and subsequent delivery to 
the liver21,22. The cholesteryl ester transfer protein (CETP) plays a pivotal role in HDL 
metabolism and in reverse cholesterol transport 23,24. 
Cholesteryl ester transfer protein (CETP), a hydrophobic glycoprotein composed of 
476 amino acids. It is a member of the lipid transfer lipopolysaccharide binding protein 
family which facilitates redistribution of cholesteryl ester and triglyceride among 
lipoproteins25. It transfers cholesteryl esters from HDL to apolipoprotein-B containing 
particles in exchange for triglycerides, thereby reducing the concentration of HDL-cholesterl 
and increasing non-HDL cholesterol, a lipoprotein distribution predisposing to atheroma 
formation26. The essential role of CETP on human lipoprotein metabolism is evident based on 
a markedly altered lipoprotein profile in patients with genetic CETP deficiency27,28. High 
plasma levels of CETP are associated with reduced HDL cholesterol levels261,29-31 and   
increased LDL cholesterol levels 32. Several studies have also shown high CETP levels to be 
atherogenic33,34. 
In humans, CETP mRNA encodes a polypeptide of Mr 53000, which is n-
glycosylated at 4 sites, giving rise to the mature form of CETP of Mr 7400035. CETP is 
expressed primarily in liver, spleen, and adipose tissue, and lower levels have been detected 
in the small intestine, adrenal gland, heart, kidney, and skeletal muscle 35,36. There is a wide 
variation in plasma CETP activity within and between population groups. 
The gene for human CETP contains 25 kb genomic DNA and is composed of 16 
exons. It has been localized on chromosome 16q21 adjacent to the lecithin-cholesterol acyl 
transferase gene. Several common restriction fragment length polymorphisms (RFLPs) have 
been reported in the CETP gene locus 37,38. 
TaqIB polymorphism is most widely studied, which is created by a silent base change 
affecting the 277th nucleotide in the first intron of the CETP gene 37,   resulting in two alleles 
B1 and B2. The CETP TaqIB polymorphism is associated with changes in plasma CETP 
concentrations, HDL cholesterol, and risk of CAD39-43. Individuals with B1 allele have higher 
CETP mass, CETP activity and low HDL cholesterol than individuals with B2 allele 40. Most 
of the reports in Asians have shown a positive association between the B1 allele and CAD 
44,45 Due to its intronic location this polymorphism cannot be considered as a part of a 
functional regulatory site, but can be a marker for another functional site. Its effect on plasma 
CETP mass and HDL-C can be accounted by its linkage with many 5′ promoter region base 
changes like −629C/A, −971G/A and −1337C/T polymorphisms 46-48. 
In view of this we have evaluated the distribution of Cholesteryl ester transfer protein 
gene Taq1B polymorphism and the concerned phonotype (Cholesteryl ester transfer protein 
activity) was analysed by using a fluorometric assay kit. 
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REVIEW OF LITERATURE 
Coronary heart disease has been defined as impairment of function of heart due to 
inadequate blood supply to the heart compared to its needs caused by atherosclerosis. It being 
a multifactorial disease has a complex etiology.  Many genetic and environmental factors act 
in combination to determine an individual’s risk of developing coronary heart disease4. A 
large number of studies such as the Framingham heart study5, The Lipid research clinic’s 
coronary primary prevention trial, the Helsenki Heart study, have been conducted to examine 
the role of risk factors for coronary artery disease. The risk factors identified by these 
epidemiological studies include a group of fixed risk factors like positive family history, age, 
male gender, and a group of modifiable risk factors like blood lipid profile abnormalities, 
hypertension, physical inactivity, obesity, cigarette smoking, alcoholism, diabetes mellitus, 
hyperhomocysteinemia5. Though overwhelming evidence particularly that given by response 
to “Response to retention hypothesis” indicates that the whole sequence of events is found to 
be initiated by the retention of modified Low Density Lipoprotein8,9, it was identified later 
that despite changes in lifestyle and the use of new pharmacologic approaches to lower 
plasma cholesterol10,11. Cardiovascular disease continues to be principal cause of  
death12,13 .  
ATHEROSCLEROSIS 
 Atherosclerosis is a disease affecting arterial blood vessels. It is a chronic 
inflammatory response in the walls of arteries, in large part due to the accumulation of 
macrophage white blood cells promoted by low density (especially small particle) 
lipoproteins without adequate removal of fats and cholesterol from the macrophages by 
functional high density lipoproteins (HDL). It is commonly referred to as a "hardening" or 
"furring" of the arteries. It is caused by the formation of multiple plaques within the arteries.  
The lesions of atherosclerosis occur principally within the innermost layer of  
the artery wall, the intima .They include14 –16, 
• Fatty streak 
• Fibrous plaque 
• Complicated lesions 
o Plaque disruption 
o Atherothrombosis 
FATTY STREAK 
 The process of atherogenesis begins in childhood with the development of fat, lipid 
rich lesions called fatty streaks. They are also found to contain macrophages, T lymphocytes, 
smooth muscle cells – each of these cells are found to contain deposits of cholesterol and 
cholesterol oleate. The lesions are yellowish and sessile in appearance and they cause little or 
no obstruction of the affected artery and no clinical sequelae. Observations suggest that lipid 
deposition does not inevitably lead to the advanced lesions of atherosclerosis but that a 
number of factors are associated with the progression of the lesions and with the development 
of more complex form of atherosclerosis, the fibrous plaque. 
FIBROUS PLAQUE 
 The fibrous plaques are derived from fatty streaks that continue the process of cell 
proliferation, lipid accumulation, and connective tissue formation and that the deep core of 
lipid and cell debris results from inadequate blood supply, inflammation, and cell necrosis. 
There is a lesion that is accepted as a forerunner of the fibrous plaque – this is known as 
fibromusculoelastic or intermediate lesion of the intima, which consists of proliferated 
smooth muscle cells surrounded by connective tissue and contains little or no lipid. A fully 
blown fibrous plaque consists of numerous smooth muscle cells surrounded by a dense 
connective tissue matrix often intermixed with numerous macrophages. This cap covers a 
deeper layer of macrophages filled with lipid that are often intermixed with variable number 
of T lymphocytes. 
ADVANCED LESIONS – PLAQUE DISRUPTION AND ATHEROTHROMBOSIS 
 The typical advanced, complicated lesion contains a large necrotic core with a fibrous 
core, loaded with macrophages. The macrophages can form numerous proteolytic enzymes, 
including metalloproteinases – these enzymes cause the removal of fibrous cap – thus plaque 
disruption is found to happen at the shoulder of the lesion where the cap is thin and the 
concentration of macrophages is the greatest. The plaque disruption allow the lesion to get 
involved in thrombotic episodes that can lead to occlusive disease17. 
Thus, atherosclerosis causes two main problems.  
1. First, the atheromatous plaques, though long compensated for by artery enlargement, 
eventually lead to plaque ruptures and stenosis (narrowing) of the artery and, 
therefore, an insufficient blood supply to the organ it feeds.  
2. Second, if the compensating artery enlargement process is excessive, then a net 
aneurysm results. 
 These complications are chronic, slowly progressive and cumulative. Most 
commonly, soft plaque suddenly ruptures, causing the formation of a thrombus that will 
rapidly slow or stop blood flow, leading to death of the tissues fed by the artery in 
approximately 5 minutes. This catastrophic event is called an infarction.  
The clinical scenario of this catastrophic event depends on which artery is affected by 
this event.  
1. One of the most common recognized scenarios is thrombosis of a coronary 
artery, causing myocardial infarction (a heart attack). This condition is called 
as Coronary artery disease. 
2. Second most common is that caused due to thrombosis of carotid artery 
branches and inadequate blood supply to brain – which presents itself as stroke 
or transient ischemic attack.  
3. Another common scenario in very advanced disease is claudication from 
insufficient blood supply to the legs, typically due to a combination of both 
stenosis and aneurysmal segments narrowed with clots. This is called as 
peripheral artery disease. 
4. Since atherosclerosis is a body-wide process, similar events also occur in the 
arteries of the intestines, kidneys, legs, etc. 
HYPOTHESIS OF ATHEROGENESIS 
 Atherosclerosis has been recognized in humans for thousands of years. Long has 
discussed the development of clinic-pathologic correlations that evolved during the era when 
autopsy examination permitted the formulation of a hypothesis relating the degree of 
atherosclerosis to the incidence of myocardial infarction and stroke13. Virchow proposed the 
idea that some form of injury to the arterial wall associated with the inflammatory response 
resulted in the degenerative lesion of atherosclerosis18. This idea was subsequently modified 
by Antischkow19 and further included the role of platelets and thrombogenesis in 
atherosclerosis as expanded by Duguid16. John French noted that the structural integrity of the 
endothelial lining20 of the artery represented a key element in the maintenance of normal 
arterial function and that alteration in endothelial integrity might precede a sequence of 
events that would lead to the various forms of the lesions of atherosclerosis. 
RESPONSE TO INJURY HYPOTHESIS 
 In normal artery, the endothelial cells form a continuous monolayer that regulates the 
passage of substances from the plasma to the underlying wall49-51, forms a thromboresistance 
surface that promotes the continuous flow of blood throughout the vascular tree52,53, by 
production of certain cytokines regulates the migration and proliferation of smooth muscle 
cells and they are metabolically active. Endothelial cells are capable of transporting plasma 
lipoproteins of given sizes into the arterial wall54. The endothelium exhibits the 
thromboresistant characters by production of three factors. They are the cell surface 
glycoproteins and proteoglycans that form the surface coat of the endothelial cells, 
prostacyclin52, and the most potent agent, nitric oxide53. Prostacyclin and NO are potent 
vasodilatory agents and potent inhibitors of platelet aggregation. The hypothesis posits that 
some form of “injury” to the endothelium results in structural and functional alterations in the 
endothelial cells, in such a way that they would permit plasma constituents such as 
lipoproteins and inflammatory cells to have a more ready access to the artery wall.  
The endothelial dysfunction is associated with overexpression of E, L, P selectin that 
appear to play a role in inducing rolling and attachment of monocytes and T lymphocytes to 
endothelium. This rolling is facilitated by the upregulation of ICAM 1 and VCAM 1 also. 
Another molecule formed by endothelium, PeCAM 1 has been shown to participate in 
interendothelial migration by the adherent leukocyte into the subendothelial space or intima 
of the artery. Thus, the earliest phase of the chronic, inflammatory response that has become 
recognized to be the hallmark of atherogenesis is represented by leukocyte adhesion due to 
the formation of these attachment and adherence molecules on the surfaces of the 
endothelium and the leukocytes55-57. 
A second event accompanying endothelial dysfunction is transmigration of lipoproteins 
particularly of small LDL particles, this transmigration places LDL in the subendothelial 
space which is virtually devoid of any antioxidant properties of the circulation, hence it gets 
oxidised. Oxidised LDL can act as one of the chemotactic reagents and can also induce the 
endothelial cells and the underlying smooth muscle cells to form a second chemotactic factor, 
monocyte chemoattractant protein 1 (MCP-1) and a colony stimulating factor (M-CSF). In 
this scenario, the monocyte gets activated to macrophages, which express SR-B1 causing 
unregulated uptake of LDL particles, forming foam cells. Such a lesion with foam cells, 
activated inflammatory cells is called as fatty streak.  
Oxidised LDL, foam cells, the activated macrophages, T-cells, produce various 
cytokines IL-1, TNF-α. Under the influence of these cytokines, endothelium, macrophages 
and T cells produce PDGF, FGF58. PDGF stimulates smooth muscle cell migration and 
proliferation. FGF stimulate the vascular smooth muscle cell to produce collagen and the 
various components of extracellular matrix together they form the fibrous cap. TNF-α 
induces apoptosis of foam cells causing exocytosis of its lipid content, which forms the lipid 
core. Such a lesion with lipid core, surrounded by activated T-cells, macrophages, platelets 
(occasionally), lined by a fibrous cap is called as a stable atherosclerotic plaque. Thus 
oxidised LDL is not only toxic to the endothelium and the surrounding cells in the intima but 
also chemotactic for monocytes and can activate monocyte derived macrophages to produce 
growth factors and cytokines. Hence it may be the principal culprit in advancing the lesions 
of atherosclerosis. 
If the injury to the endothelium were a self-limited event and if endothelial function 
were restored, the proliferative lesions might be capable of regressing. If this were the case, 
the lesions would be reversible and, if they had not reached a critical size, would be clinically 
silent. On the other hand, if the injury at focal sites in the artery wall is either of long standing 
or chronically repeated over period of many years, the lesion could continue to progress, 
becoming increasingly complex in terms of their composition. Because, the atherosclerotic 
plaque does not only have smooth muscle cells but also macrophages, which are capable of 
producing metalloproteinases and TNFα, both of which cause necrosis and digestion of the 
fibrous cap, this loss of fibrous cap is responsible for the complications of atherosclerosis, 
namely plaque rupture. This plaque rupture exposes the subendothelial extracellular matrix to 
the factors of coagulation in the circulation initiating the intrinsic pathway of coagulation – 
this is responsible for atherothrombosis.  
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Age 
In many epidemiologic surveys, age remains one of the strongest predictors of 
disease. The majority of patients with atherosclerotic coronary heart disease are more than 65 
years old.  Older patients have higher mortality and more complications. Age related changes 
in the cardiovascular system and other organs make it reasonable to assume that aging per se 
constitutes a major reason for the increased morbidity and mortality in older persons. These 
age related changes include diastolic dysfunction, degenerative changes in the conduction 
system, reduced responses to catecholamine and sympathetic stimuli. 
  
Male sex 
 The relationship of gender to the development and prognosis of atherosclerotic 
coronary heart disease is complicated59. The powerful protective effect of the premenopausal 
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Fig 2 ROLE OF AGING IN ATHEROSCLEROSIS 
state in preventing and postponing the condition is fully appreciated; women tend to develop 
atherosclerotic coronary heart disease approximately 10 years later than men. Typical and 
atypical symptoms of angina pectoris are less likely to be associated with significant 
epicardial coronary atherosclerosis in women especially in those under the age of 6059,60. 
Complications are fewer in women after the onset of angina, but they may be more frequent 
after myocardial infarction61,62. However there are multiple reports indicating a gender bias in 
reference to the use of diagnostic and therapeutic procedures, but interpretation is 
complicated by the possibility of overuse and overtreatment in low risk men63-67. The point 
has been clearly made however; atherosclerotic coronary heart disease manifest as angina, 
infarct, and sudden death is as common in women after age 60 as it is in men. 
 This gender dependent differential risk is attributed to the protective function exerted 
by estrogens. Recently, a study of estrogens and their effect on smooth muscle cells and the 
other elements of atherogenesis showed that estrogens have an antiproliferative effect on 
smooth muscle cells and can be protective to the endothelium in relation to stimulation by 
growth factors, cytokines and other agents. Estrogen is not only antiproliferative for smooth 
muscle but also has been shown to be capable of modulating acetylcholine mediated dilation 
of atherosclerotic coronary arteries68.   
Family history of Early- Onset CHD 
 Over 35 case-control and prospective studies have consistently identified an 
association between CHD and a history of first degree relatives with early onset CHD69. This 
risk generally persists even after adjustment for other risk factors. The family history most 
predictive of coronary disease is that of a first degree relative developing CHD at an early 
age. Although CHD in a male relative with onset at age 55 or less or a female relative with 
onset at age 65 or less is defined as a positive family history70, the larger the number of 
relatives with early onset of CHD or the younger the age of CHD onset in the relative, the 
stronger the predictive value 71,72. 
Socioeconomic status 
 A consistent relationship has been devised between lower socioeconomic status and 
atherosclerosis. There has been the perception that conventional risk factors cluster in lower 
socioeconomic groups and that this phenomenon can explain the increased incidence of 
atherosclerotic coronary heart disease73. But, only 50% of atherosclerotic coronary heart 
disease can be explained by known risk factors. The socioeconomic status proved to be 
independent predictors in patients with established atherosclerotic coronary heart disease74. 
Although no simple relationship between socioeconomic status, risk for cardiovascular 
disease and long term outcome for manifest atherosclerotic coronary heart disease can be 
devised, the evident is consistent and persuasive that lower socioeconomic status is an 
independent and significant determinant of long-term outcome. 
Hypertension 
 Several major prospective epidemiological studies have found that both systolic and 
diastolic hypertension have a strong, positive and graded relationship to CHD without 
evidence level of a threshold risk level of blood pressure75-77. The risk imposed by 
hypertension is heightened substantially when other risk factors are present. Hypertension 
clusters with insulin resistance, hyperinsulinemia, glucose intolerance, dyslipidemia, left 
ventricular hypertrophy and obesity and occurs in isolation in fewer than 20% of 
individuals78. 
 The potential mechanisms by which hypertension may cause impaired endothelial 
function include increased endothelial permeability to lipoproteins, increased adherence of 
leukocytes, increased oxidative stress, and hemodynamic stress that may trigger acute plaque 
rupture, all these mediated by activation of NF-kB pathway and inactivation of eNOS 
enzyme.  
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 Hyperglycemia 
 Hyperglycemia is an independent risk factor for CHD, increasing the risk by two to 
three times for men and three to five times for women79. CHD is the leading cause of death in 
diabetic patients and approximately 25% of MI survivals have diabetes 80. The CHD risk for a 
premenopausal diabetic woman is similar to the risk of a nondiabetic man, hence diabetes 
abolishes the protective effect of being a premenopausal female81. Diabetic women have 
twice the risk of recurrent MI compared with diabetic men82. The greater risk of CHD in 
diabetic women compared to diabetic men may be explained in part by the greater adverse 
effect of diabetes on lipoproteins in women 83.  
 Potential mechanisms by which hyperglycemia may cause atherosclerosis include 
impaired endothelial function, glycation of LDL,  enhanced lipoprotein oxidation, increased 
fibrinogen, increased platelet aggregation, increased PAI-1, impaired fibrinolysis, increased 
small LDL. All these are attributed to the increased flux of glucose into glycolysis (glucose 
uptake and hexokinase activity in endothelium is insulin independent),  as a result there is an 
increased NADH/NAD ratio, causing increased   flux of electrons through electron transport 
chain, producing superoxide radicals. This cause DNA damage and the resultant ADP 
ribosylation of proteins inhibit glyceraldehyde 3-phosphate dehydrogenase of glycolysis, 
causing accumulation of glyceraldehyde 3- phosphate and its precursor fructose 6-phosphate. 
The former cause activation of protein kinase C pathway through DAG – protein kinase C 
pathway stimulates the production of various cytokines and thereby stimulates inflammation. 
Fructose 6 phosphate stimulates hexosamine pathway, thereby stimulate N- glycosylation of 
many proteins like eNOS and inhibition of them, this causes NOS uncoupling and the 
resultant oxidative stress further aggravates the condition. Furthermore, there is increased 
formation of advanced glycation end product, which on binding to receptor for advanced 
glycation end products is found to stimulate NF-kB pathway, causing all the features of 
atherosclerosis. 
Fig 4. PATHOGENESIS OF ATHEROSCLEROSIS IN  
DIABETES MELLITUS 
 
 
 
 
 
Insulin resistance and hyperinsulinemia 
 Resistance to insulin and compensatory hyperinsulinemia are the common metabolic 
basis of cluster of coronary risk factors, particularly hypertension, diabetes, 
hypertriglyceridemia, low HDL, predominance of small LDL, and an increased plasminogen 
activator inhibitor concentration84,85.  Hyperinsulinemia may raise blood pressure through 
sympathetic nerve stimulation and/or renal sodium retention. Insulin sensitivity is associated 
with endothelial nitric oxide production in healthy persons providing a clue as to how insulin 
resistance may promote CHD directly86. Furthermore, hyperinsulinemia has been found in a 
prospective study to be an independent risk factor for CHD in nondiabetic men after adjusting 
for body weight, blood pressure and dyslipidemia87. 
Physical inactivity 
 Physical inactivity roughly doubles the risk of CHD. Moderate intensity exercise 
reduces coronary atherosclerosis and widens coronary arteries in monkeys fed on atherogenic 
diet compared with monkeys fed the same diet but forced to be sedentary88. Physical activity 
slows progression of angiographically defined coronary atherosclerosis in human89. Over 50 
obsevational studies, primarily of men, have established that physical fitness, on the job of 
physical activity, and leisure time physical activity reduce the risk of CHD90. Higher levels of 
physical fitness and leisure time physical activity are associated with lower rates of mortality, 
independent of other risk factors90. The risk of MI and sudden cardiac death is greatest during 
exercise, leading some to question the benefits of exercise91. The overall risk of myocardial 
infarction and sudden cardiac death, is however low among those who exercise regularly. The 
greatest reduction in risk is between sedentary individuals and those who do regular moderate 
intensity activity.  
 In addition to decreasing myocardial oxygen demand and increasing myocardial 
efficiency and electrical stability, other potential mechanisms by which physical activity may 
reduce CHD risk include increasing HDL, reducing blood pressure, reducing obesity, 
improving insulin sensitivity, decreasing platelet aggregation and increasing fibrinolysis90.. 
Obesity 
 Obesity promotes insulin resistance, hyperinsulinemia, hypertriglyceridemia, low 
HDL cholesterol, and LVH 92,93. Many observational studies have found that obesity strongly 
and positively correlates with the risk of CHD in univariate analysis. In multivariate analysis, 
when controlling statistically for risk factors such as hypertension, diabetes, and 
dyslipidemia, obesity is not found to be an independent risk factor. Rather it reflects that 
much of the adverse consequences of obesity are mediated through resultant metabolic risk 
factors acting as pathological links in the causal pathway. Nevertheless, some large 
prospective observational studies of long duration indicate that obesity is an independent risk 
factor for coronary and cardiovascular mortality in men and women94-96. The central 
distribution of body fat predicts CHD in men independently of body-mass index and other 
major risk factors97. Weight loss improves insulin sensitivity and glucose disposal; reduces 
blood pressure, triglycerides and LVH; and increases HDL cholesterol92,93. 
Oxidative stress 
 Excessive production of reactive oxygen species has been implicated to play an 
important role in a number of cardiovascular pathologies, including hypertension, 
atherosclerosis, myocardial infarction, ischemia/reperfusion injury. ROS are generated in 
vascular cells by NADPH oxidases, uncoupled eNOS, and other enzymatic sources or as a 
product of mitochondrial respiration59. If this production goes unbalanced, it leads to 
exacerbation of pathophysiological processes. Superoxide radicals are found to cause 
oxidative modification of LDL. Oxidised LDL, by activating NF-kB pathway of 
inflammation is found to mediate the increased production of IL-1, increased expression of 
ICAM, both of which mediate the rolling of inflammatory cells. Furthermore there is 
increased production of PDGF and FGF, both of which cause smooth muscle cell 
proliferation and migration. This cycle is reinforced by the decreased production of NO, 
because the superoxide cause nitrosylation of eNOS and thereby it inhibits the enzyme 
activity. The decreased NO causes increased vascular reactivity and the resultant shear stress 
will further stimulate NF-kB pathway. Thus oxidised LDL is hypothesized to play a major 
role in the initiation and progression of atherosclerosis98-101.  
 
 
 
 
 
 
 
 
 
Fig 5. ROLE OF OXIDATIVE STRESS IN ATHEROSCLEROSIS 
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Cigarette smoking 
 Strong dose relationships between cigarette smoking and coronary heart disease have 
been observed in both sexes. Cigarette smoking increases the risk two to threefold and 
interacts with other risk factors to multiply risk. Pathophysiological studies have identified a 
panoply of mechanisms through which cigarette smoking may cause CHD. Smokers have 
increased levels of oxidation products, including oxidised LDL. Cigarette smoking also 
lowers the cardioprotective levels of HDL. These effects, along with direct effects of carbon 
monoxide and nicotine, produce endothelial damage. Possibly, through these mechanisms, 
smokers have increased vascular reactivity102. Cigarette smoking is also related to increased 
levels of fibrinogen103 and increased platelet aggregability104. Thus cigarette smoking paves 
way for atherosclerosis by inducing oxidative stress and by altering coagulability. 
Dyslipidemia 
Total cholesterol and LDL cholesterol 
 Numerous prospective studies have identified a continuous, graded and direct 
relationship between serum cholesterol and CHD incidence105. The level of total and LDL 
cholesterol interacts with other risk factors to multiply risk106. Elevated LDL cholesterol 
levels have been related to recurrent events and CHD death in patients with established CHD 
107. Elevated LDL cholesterol levels appear to be involved with all stages of atherogenesis – 
endothelial dysfunction, plaque formation and growth, and plaque instability and disruption. 
Elevated cholesterol levels in the plasma lead to an increased retention of LDL particles in 
the arterial wall, their oxidation and the secretion of various inflammatory mediators and 
chemoattractants108. LDL is also a potent mitogen for smooth muscle cells; progressive 
growth of atherosclerotic plaques can be halted by lowering of LDL cholesterol levels. 
Atherosclerotic plaques with a large lipid core and numerous lipid filled macrophages are 
prone to rupture109. Thus the epidemiological evidence strongly supports LDL-cholesterol’s 
role in atherosclerosis. 
 Furthermore, small dense LDL is felt to be more atherogenic110. Possible explanation 
for this is that when a person has more of small LDL particles, for  given cholesterol content, 
the number of LDL particles will be more, and an LDL receptor can accept only one LDL 
particle at a time and hence the rate of metabolism of LDL is decreased, causing 
accumulation of LDL in the plasma. The second reason for the same is the endothelium will 
be more permeable to small LDL particle when compared to a normal LDL. 
Triglycerides 
 The relationship between triglycerides and CHD has been less clear. In men, 
univariate analysis has consistently demonstrated a direct dose-response relationship. This 
relationship usually disappears after adjustment for other risk factors such as HDL 
cholesterol, obesity, and diabetes111. Hypertriglyceridemia however has been found to be an 
independent risk factor in women112. Several mechanisms have been proposed to explain the 
triglyceride- CHD association. First, some patients with hypertriglyceridemia have a 
predominance of small, dense LDL particles. Second, fasting hypertriglyceridemia may be a 
marker of exaggerated postprandial hyperlipidemia, which may promote the uptake of 
atherogenic triglyceride rich lipoprotein remnants by endothelial cells113. Finally, serum 
triglyceride levels are strongly related to fibrinogen and factor VII in numerous 
epidemiological studies114. Therefore, number of mechanisms, direct and indirect link serum 
triglycerides and CHD. 
 
Low HDL cholesterol 
 Numerous prospective epidemiological studies have demonstrated a continuous, 
inverse relationship between HDL cholesterol levels and the incidence of CHD115. The total 
cholesterol to HDL cholesterol ratio is a better predictor of CHD than the HDL cholesterol 
level alone115. Two important mechanisms by which HDL is thought to play a protective role 
against atherosclerosis are reverse cholesterol transport and inhibition of LDL oxidation. 
Reverse cholesterol transport 
 The key role of HDL as a carrier of excess cellular cholesterol in the reverse 
cholesterol transport pathway is believed to provide protection against atherosclerosis. In 
reverse cholesterol transport, peripheral tissues (e.g., vessel-wall macrophages) remove their 
excess cholesterol through the ATP-binding cassette transporter-1 (ABCA1) to poorly 
lipidated apolipoprotein A-I, forming pre-beta-HDL. Lecithin-cholesterol acyltransferase 
then esterifies free cholesterol to cholesteryl esters, converting pre-beta-HDL to mature 
spherical alpha-HDL. HDL cholesterol is transported to the liver by two pathways. Through 
the first pathway, it is delivered directly to the liver through interaction with the scavenger 
receptor, class B, type I (SR-BI). Through the second pathway, cholesteryl esters in HDL are 
transfered by the cholesteryl ester transfer protein (CETP) to very-low-density lipoproteins 
(VLDL) and low-density lipoproteins (LDL) and are then returned to the liver through the 
LDL receptor. HDL cholesterol that is taken up by the liver is then excreted in the form of 
bile acids and cholesterol, completing the process of reverse cholesterol transport. 
Cholesteryl ester transfer protein is a plasma glycoprotein that plays an important role 
in reverse cholesterol transport. It transfers cholesteryl esters from HDL to LDL and VLDL 
particles in exchange for TG, thereby reducing the concentration of HDL cholesterol and 
increasing non-HDL cholesterol, a lipoprotein distribution predisposing to atheroma 
formation.  
Direct proof of a role for cholesteryl ester transfer protein in the development of 
atherosclerosis has been provided in mouse models. Marotti et al116 demonstrated that 
transgenic mice expressing CETP had much worse atherosclerosis than did non-expressing 
controls, and they suggested that the increase in lesion severity was due largely to CETP-
induced alterations in the lipoprotein profile.  
CHOLESTERYL ESTER TRANSFER PROTEIN 
Plasma cholesteryl ester transfer protein (CETP) is a hydrophobic glycoprotein, with 
an Mr of 70,000 to 74,000 35. It belongs to a family of proteins that engage in lipid binding 
and lipid transfer 36. CETP is secreted mainly from the liver and that circulates in plasma, 
bound mainly to HDL 29. Analysis of human plasma by gel filtration or apolipoprotein A-I 
immunoaffinity chromatography indicates that the major part (> 80%) of CETP is associated 
with HDL particles. Although CETP binds with similar affinity to VLDL, LDL, and HDL, 
the molar concentration of plasma HDL is much higher than that of plasma VLDL or LDL, 
explaining the predominant association with HDL in plasma 117. CETP dissociates from 
lipoproteins during ultracentrifugation. 
 
CETP promotes the redistribution of cholesteryl esters, triglycerides, and, to a lesser 
extent, phospholipids between plasma lipoproteins. CETP transfers lipids from one 
lipoprotein particle to another in a process that results in equilibration of lipids between 
lipoprotein fractions. CETP contributes to an atherogenic lipid phenotype in several ways. It 
increases the cholesteryl ester content and thus, the atherogenicity of VLDL and LDL. The 
CETP-mediated reduction in HDL particle size is accompanied by the dissociation of lipid-
poor apolipoprotein A-I (apoA-I) from the particle. 
 
STRUCTURE OF CHOLESTERYL ESTER TRANSFER PROTEIN 
Human CETP consists of 476 amino acid residues. The amino acid analysis of 
purified CETP showed an unusually high content (44%) of non-polar residues. The CETP 
complementary DNAs (cDNAs) were cloned from humans, rabbits, cynomolgus monkeys 
and hamster. Human CETP cDNA has an approximately 80% homology to that of rabbits.  
 
CETP belongs to a family of proteins that engage in lipid binding 
(lipopolysaccharide-binding protein (LBP) and bactericidal/permeability-increasing protein 
(BPI)) and lipid transfer (CETP and PLTP) 36, but emerging family members may have other 
functions 118. Although these four proteins possess different physiological functions, they 
share marked biochemical similarities. All of these four proteins can bind lipopolysaccharides  
and phospholipids as well as a variety of other lipids. CETP, PLTP and LBP are associated 
with plasma HDL; however, BPI exists on the membranes of secretory granules of 
neutrophils. BPI is a long boomerang-shaped molecule having two domains at the NH2- and 
COOH-terminus with similar folds shaped like barrels. BPI contains a central beta -sheet 
domain which forms an interface between the barrels. Each barrel has a pocket occupied by a 
phosphatidylcholine molecule. CETP may have a similar structure.  
 
28% of molecular mass of CETP is attributed to N-glycosylation at residues 88, 240, 
341 and 396119 The high content of glycosylation, hydrophobic residues and free cysteines 
(five) presented significant challenges for structural studies. 
 
CETP has an elongated ‘boomerang’ shape with dimensions of 135 A° X 30 A° X 35 
A° and a fold homologous to that of BPI118. The fold consists of two similar domains 
connected by a linker, residues 240–259 in CETP (Fig. 6a). The structure of CETP can be 
divided into four structural units: one barrel at each end of the protein (barrels N and C), a 
central beta-sheet between the two barrels and a C-terminal extension that is not present in 
BPI (Fig. 6b). Each barrel contains a highly twisted beta-sheet and two helices (A and B in 
barrel N, A′ and B′ in barrel C), with helices B and B′ being longer than A and A′. The 
central beta-sheet includes six antiparallel strands consisting of residues before and after the 
barrels. These three structural units in CETP overlay well with the homologous units in BPI. 
The fourth unit, Glu465–Ser476 at the C terminus of CETP, forms a distorted amphipathic 
helix, helix X that unwinds slightly at the end.  
 
The structure of CETP reveals four bound lipid molecules, which must have been 
incorporated during protein production, as no lipid was introduced after expression. CETP 
has two neutral lipid– binding sites and two phospholipid-binding sites. The four lipids 
occupy a 60-A°-long, continuous tunnel that traverses the core of the protein. The CETP 
tunnel is formed by a wall of beta-sheets underneath the bound lipids and a layer of helices 
above the lipids (Fig. 6b). The CETP concave surface is the site of the N and C openings, 
helix X and the Ω1 flap, making this surface the most likely to bind lipoproteins (Fig. 6a). 
The surface contains numerous charged and hydrophobic residues that are distributed evenly 
rather than in distinct patterns, suggesting evenly distributed interactions with lipoprotein 
surfaces. The sheer size of the interface and the apparent lack of a ‘hot spot’ suggest that 
small alterations of the concave surface should not greatly change lipoprotein affinity and 
explain the lack of detectable activity changes in concave-surface mutants. 
 
 Figure 6 :  Overall structure of CETP. (a) Ribbon diagram of N-terminal (green) and C-
terminal (yellow) domains, with linker in red. N-terminal side is shown on left. CE1 
(magenta) and CE2 (cyan) are shown as space fills and phospholipid as black bonds. N-
glycosylation sites are shown as blue bonds, with 341 and 396 labelled. ‘5’ marks the 
observed N terminus. Helices A, B, A, B and X are labelled. Helix X belongs to the C-
terminal domain but interacts with residues of the N-terminal domain. (b) The view after a 
90° rotation. The four structural units shown are barrel N (green), central beta-sheet (orange), 
barrel C (yellow) and helix X (cyan). The Ω1 flap is in grey. N-glycosylation sites 88 and 240 
are labelled. (c, d) Cα traces of CETP (yellow) and BPI (purple) with the barrel Ns (c) or 
barrel Cs (d) overlaid. CETP-bound phospholipid molecules are in red. 
SYNTHESIS OF CHOLESTERYL ESTER TRANSFER PROTEIN 
 
CETP is synthesized by the liver, spleen, small intestine, adipose tissues, adrenal 
gland, kidney, heart, and skeletal muscles 35,36. CETP is secreted by a variety of cell types, 
including monocyte-derived macrophages, B-lymphocytes, adipocytes, hepatocytes and a 
human hepatoma cell line, HepG2 cells, and CaCo-2 cells 29. In cynomolgus monkeys, high 
levels of CETP mRNA were shown in the liver and thoracic aorta. Tissues containing LPL 
such as adipose tissues and skeletal muscles were shown to be the major sources of CETP 
mRNA in hamsters. There is a marked species difference in CETP activity. CETP activity is 
very low in mice and rats and high in rabbits. The CETP activity in humans is intermediate 
between mice and rabbits. 
  
Human cultured monocyte-derived macrophages synthesize and secrete CETP 
activity. Induction of CETP expression occurs during the differentiation of monocytes into 
macrophages. The secretion of CETP activity into culture medium is facilitated by 
cholesterol loading with acetylated LDL or free cholesterol. The intracellular accumulation of 
cholesteryl ester is positively correlated with the secretion of CETP, suggesting that CETP 
may function to maintain intracellular cholesterol homeostasis during differentiation and in 
response to an excess of cholesterol accumulation. CETP mRNA abundance in human 
adipose tissue was demonstrated to be a function of membrane cholesterol content rather than 
lipid droplet cholesterol. 
 
CETP activity is also detected in seminal fluid and cerebrospinal fluid, which is about 
12% of that of plasma 120. CETP activity can be detected in the conditioned medium from 
human neuroblastoma and neuroglioma cells and from sheep choroid plexus. Therefore, it is 
suggested that CETP may play some roles in the transport and redistribution of lipids within 
the central nervous system and adipocytes. 
 
ALTERNATIVE SPLICING OF CETP mRNA 
 
Two isoforms (Figure:7-A and B) of CETP mRNA were demonstrated in human 
tissues expressing the CETP gene; one was a full-length form which produces an active Mr 
74 000 CETP, and the other a shorter variant in which exon 9-derived sequences had been 
removed 121. The exon 9-deleted form of CETP mRNA is produced by alternative splicing of 
the CETP gene transcript. Exon 9 contains 180 nucleotides within the amino acid encoding 
sequence of the CETP mRNA. The splicing of exon 9 results in the removal of 60 amino 
acids from the CETP sequence, without alteration of the translational reading frame. The 
alternatively spliced CETP mRNA is present in all human tissues containing the CETP 
mRNA, but its abundance varies from about 20% of total CETP mRNA in liver to 40-60% in 
spleen. 
 
By transfection of the exon 9-deleted cDNA to COS (CV-1 origin, SV-40) cells, a 
shortened, poorly secreted and inactive form of CETP was produced. When full-length and 
exon 9-deleted cDNAs were co-transfected to COS cells, the secretion of full-length active 
CETP was inhibited. Therefore, the exon 9-deleted protein may have a dominant negative 
effect on the expression of full-length CETP and alternative splicing of the CETP gene may 
modulate the level of active CETP. 
 
The Caco-2 (colorectal adenocarcinoma) cells, a model cell line of intestines, show a 
low rate of active CETP mRNA under basal conditions and about 60% of reverse transcribed 
CETP cDNA corresponds to exon 9-deleted transcripts. However, addition of sodium oleate 
into the culture medium induces a 2-fold increase in full-length CETP cDNA transcripts 
without affecting exon 9-deleted transcripts, resulting in an enhancement of CETP activity 
secreted into the medium. Thus, alternative splicing of the human CETP gene in each tissue 
may modulate the expression of active CETP.  
 
STRUCTURE FUNCTION RELATIONSHIP OF CETP 
 
The epitope of a neutralizing monoclonal antibody was shown to be the carboxyl (C)-
terminal sequences of CETP (26 amino acids), which are important for neutral lipid transfer 
activity 122. Some monoclonal antibodies completely inhibited triglyceride transfer, but not 
cholesteryl ester transfer, suggesting that the binding sites of cholesteryl ester and triglyceride 
may be different. The C-terminal sequence -Phe-Leu-Leu-Leu- (residues 454-457) was 
essential for normal binding of CETP to each lipoprotein and the effective transfer of 
cholesteryl ester and triglyceride, possibly together with the other sequences in the C-
terminal region. Interestingly, a similar conserved sequence exists in several other proteins 
that function in binding non-polar lipids, including LCAT, cholesterol 7α - hydroxylase, 
cholesterol esterase, and hormone-sensitive lipase. The Mr of CETP polypeptide deduced 
from the cDNA is 53108; however, purified plasma CETP appears as a broad band 
containing two different molecular forms. This micro-heterogeneity could be explained by 
the variable N-linked glycosylation. 
 
FIG : 7 COMPARISON OF AMINOACID SEQUENCES OF ISOFORM I(A) AND 2 (B) OF CETP   
A       10         20         30         40         50         60  
MLAATVLTLA LLGNAHACSK GTSHEAGIVC RITKPALLVL NHETAKVIQT AFQRASYPDI  
        70         80         90        100        110        120  
TGEKAMMLLG QVKYGLHNIQ ISHLSIASSQ VELVEAKSID VSIQNVSVVF KGTLKYGYTT  
       130        140        150        160        170        180  
AWWLGIDQSI DFEIDSAIDL QINTQLTCDS GRVRTDAPDC YLSFHKLLLH LQGEREPGWI  
       190        200        210        220        230        240  
KQLFTNFISF TLKLVLKGQI CKEINVISNI MADFVQTRAA SILSDGDIGV DISLTGDPVI  
       250        260        270        280        290        300  
TASYLESHHK GHFIYKNVSE DLPLPTFSPT LLGDSRMLYF WFSERVFHSL AKVAFQDGRL 
       310        320        330        340        350        360  
MLSLMGDEFK AVLETWGFNT NQEIFQEVVG GFPSQAQVTV HCLKMPKISC QNKGVVVNSS 
       370        380        390        400        410        420  
VMVKFLFPRP DQQHSVAYTF EEDIVTTVQA SYSKKKLFLS LLDFQITPKT VSNLTESSSE  
       430        440        450        460        470        480  
SVQSFLQSMI TAVGIPEVMS RLEVVFTALM NSKGVSLFDI INPEIITRDG FLLLQMDFGF  
       490  
PEHLLVDFLQ SLS 
B        10         20         30         40         50         60  
MLAATVLTLA LLGNAHACSK GTSHEAGIVC RITKPALLVL NHETAKVIQT AFQRASYPDI  
        70         80         90        100        110        120  
TGEKAMMLLG QVKYGLHNIQ ISHLSIASSQ VELVEAKSID VSIQNVSVVF KGTLKYGYTT  
       130        140        150        160        170        180  
AWWLGIDQSI DFEIDSAIDL QINTQLTCDS GRVRTDAPDC YLSFHKLLLH LQGEREPGWI 
       190        200        210        220        230        240  
KQLFTNFISF TLKLVLKGQI CKEINVISNI MADFVQTRAA SILSDGDIGV DISLTGDPVI  
       250        260        270        280        290        300  
TASYLESHHK AVLETWGFNT NQEIFQEVVG GFPSQAQVTV HCLKMPKISC QNKGVVVNSS  
       310        320        330        340        350        360  
VMVKFLFPRP DQQHSVAYTF EEDIVTTVQA SYSKKKLFLS LLDFQITPKT VSNLTESSSE  
       370        380        390        400        410        420  
SVQSFLQSMI TAVGIPEVMS RLEVVFTALM NSKGVSLFDI INPEIITRDG FLLLQMDFGF 
       430  
PEHLLVDFLQ SLS 
 
MECHANISM FOR NEUTRAL-LIPID TRANSFER 
 
The structure of the concave surface indicates that CETP can bind only one 
lipoprotein at a time. This provides strong support for the proposal that CETP operates by a 
carrier mechanism, in which CETP accepts neutral lipids from a donor particle, shuttles them 
through the aqueous phase and delivers them to an acceptor lipoprotein. In the more 
physiologically relevant hetero-exchange 123, CETP filled with cholesteryl ester (Figure: 8, 
step 1) binds VLDL and releases the bound phospholipid. As VLDL is triglyceride rich, one 
or two triglycerides can enter the tunnel and deposit an equal amount of cholesteryl ester into 
VLDL. The triglyceride-bound CETP departs from VLDL carrying two phospholipids from 
the surface and travels through the aqueous plasma (step 2). It then engages HDL and 
releases the bound phospholipid (step 3). As HDL is cholesteryl ester rich, one or two new 
cholesteryl esters can enter the tunnel and an equal amount of bound triglyceride is deposited 
into HDL. The cholesteryl ester–filled CETP departs from HDL carrying two phospholipids 
from the surface (step 4) and hence completes a full cycle of hetero-exchange. The 
nonspecific nature of the tunnel suggests similar binding affinities for cholesteryl ester and 
triglyceride, consistent with CETP-mediated transfers being determined by the relative lipid 
compositions in lipoproteins. 
 
Figure 8:  Proposed mechanism for CETP-mediated heteroexchange. VLDL (large 
circles) is normally triglyceride (TG) rich and HDL (smaller circles) is cholesteryl ester (CE) 
rich. Step 1, CETP filled with CE (as in the crystal structure) binds VLDL and releases the 
bound phospholipid (phosphatidylcholine, PC). One or two TGs enter the tunnel and an equal 
amount of CE is deposited into VLDL. Step 2, the TG-bound CETP dissociates from VLDL 
carrying two phospholipids from the surface, leaving the VLDL particle with a higher CE 
content. Step 3, the TG-bound CETP engages HDL and releases the bound phospholipid. One 
or two new CEs enter the tunnel and an equal amount of TG is deposited into HDL. Step 4, 
the CE-filled CETP dissociates from HDL carrying two phospholipids from the surface and 
completes a full cycle of heteroexchange, which results in a lower CE content in HDL. 
 
 
ROLE OF CETP IN PLASMA LIPID TRANSPORT AND IN ATHEROSCLEROSIS 
 
The cardioprotective role of HDL is commonly explained by its function in the 
reverse cholesterol transport pathway, whereby excess cholesterol in peripheral tissues or 
atherosclerotic plaque is transported from vascular tissue back to   the liver for metabolism 
and excretion in the bile. 
Cholesteryl esters can be delivered directly to the liver by the interaction of HDL 
particles with the hepatic SR-B1 receptor or indirectly following the cholesteryl ester transfer 
protein (CETP) process.  
Cholesteryl ester transfer protein plays an important role in reverse cholesterol 
transport. It transfers cholesteryl esters from HDL to LDL and VLDL particles in exchange 
for triglyceride, thereby reducing the concentration of HDL cholesterol and increasing non-
HDL cholesterol, a lipoprotein distribution predisposing to atheroma formation. The 
cholesteryl ester in VLDL and LDL particles can then be taken up by all cells (both in liver 
and peripheral tissues) that express the LDL receptor (LDLr). Modified (oxidized) LDL is 
also taken up by macrophages in a scavenger receptor-mediated process that converts the 
macrophage into a foam cell. Accumulation of these foam cells in the arterial wall causes a 
chronic inflammatory reaction which leads to atherosclerosis. (Figure: 9) 
The relationship of CETP to atherosclerosis was studied in a group of 28 cynomolgus 
monkeys fed high fat, high cholesterol diets for 5 years 150. In these animals plasma CETP 
concentration showed a strong inverse correlation with HDL cholesterol concentration, and a 
positive correlation with LDL cholesterol concentration and with LDL molecular weight. The 
extent of coronary artery atherosclerosis was positively correlated with LDL cholesterol 
concentration and with plasma CETP concentration. In multiple regression analysis only LDL 
cholesterol concentration appeared as an independent variable significantly correlated with 
coronary artery atherosclerosis. Thus, the positive correlation of CETP with atherosclerosis 
appeared to be due to its relationship with LDL cholesterol concentration. In cynomolgus 
monkeys the plasma CETP concentration appears to be a major determinant of the 
atherogenicity of the plasma lipoproteins, probably because CETP transfers  from non-
atherogenic or anti-atherogenic HDL to atherogenic LDL (or its precursors), and also because 
CETP may influence LDL particle number.  
 
In many human dyslipidemias associated with accelerated atherosclerosis, there is an 
increase in plasma CETP concentration and/or an increase in the rate of net transfer of 
cholesteryl ester from HDL to apolipoprotein B-containing lipoproteins in incubated plasma. 
These include   dysbetalipoproteinemia124, familial hypercholesterolemia121, nephrotic 
syndrome125, hypercholesterolemia126,  insulin dependent diabetes mellitus 127, and peripheral 
vascular disease 128.  
 
Alcoholism, typically associated with increased HDL and decreased atherosclerosis, 
is associated with diminished CETP concentration 129. Exercise conditioning, associated with 
increases in HDL and decreases in LDL cholesterol, is associated with decreased CETP 
concentration 130.  
 
The introduction of CETP into rats by injection or into mice by transgenesis 116 results 
in lipoprotein changes normally associated with the development of atherosclerosis. 
 
FIG 9: ROLE OF CETP IN PLASMA LIPID TRANSPORT AND IN 
ATHEROSCLEROSIS 
  
 
 
REGULATION OF CETP ACTIVITY OR EXPRESSION BY DIFFERENT  
FACTORS 
 
The induction of hepatic CETP mRNA and plasma CETP by an atherogenic diet has 
been documented in rabbits, in cynomolgus and African Green monkeys, and in transgenic 
mice expressing the human CETP gene with its natural flanking sequences 131. Detailed 
analysis of dietary variables shows that it is the cholesterol component of the diet which is 
largely responsible for the increase in CETP mRNA and protein. Exercise conditioning is 
associated with decreased plasma CETP concentration in human subjects, which may reflect 
both decreased adiposity and more effective insulin action. Plasma CETP concentration is 
inversely related to parameters of effective insulin action 132. These findings suggest that 
CETP mRNA in adipose and muscle could be decreased during feeding as a result of insulin 
action. The increase in CETP mRNA during fasting could be linked to the mobilization of 
fatty acids from the periphery, resulting in lipoprotein synthesis in the liver. 
  
Plasma CETP is also altered by steroid hormone and drug stimuli. Plasma CETP 
activity is decreased as plasma cholesterol declines during pregnancy in the rabbit; however, 
plasma CETP is increased during the third trimester of human pregnancy, suggesting an 
effect of sex hormones on CETP expression. Corticosteroid therapy is associated with a 
reduction of plasma CETP in normal subjects and in patients with nephrotic syndrome 125.  
 
Probucol therapy is associated with pronounced increases in plasma CETP 133.  
Unexpectedly, probucol lowered CETP mRNA in human adipose tissue. The effect of 
probucol on CETP mRNA in cells may be conditioned by the cell's cholesterol pools. 
 
Only limited information is available on the regulation of CETP expression in 
cultured cells, owing to the very low expression of CETP mRNA and protein in transformed 
cell lines. Several lines of evidence indicate that a variety of cell types respond to an increase 
in cholesterol load by increasing CETP secretion. Martin et al.134 have determined the effects 
of apolipoprotein E genotype on the plasma lipoprotein and CETP responses to cholesterol 
feeding in young normal male subjects under rigorously controlled dietary conditions. ApoE 
genotype has significant and opposite effects on plasma CETP and HDL-C responses to 
dietary cholesterol in humans. One explanation for the effect of apolipoprotein E genotype on 
CETP levels is that CETP might be catabolized in association with remnant particles.  
 
Lipolysis of VLDL by lipoprotein lipase stimulates the CETP-mediated transfer of 
cholesteryl ester from HDL to VLDL. This phenomenon is related to accumulation of fatty 
acids in the surface of VLDL, which greatly enhances the binding of CETP to these particles. 
Also, lipolysis increases the binding of CETP to HDL, as a result of enrichment of HDL with 
phospholipids and fatty acids. HDL isolated from postprandial plasma is phospholipid 
enriched and acts as a more efficient substrate for CETP than fasting HDL 135. A similar 
stimulation of transfer can be produced by the action of hepatic lipase or by the direct 
addition of fatty acids to the lipoprotein mixture. Barter and colleagues 136 have shown that 
the addition of fatty acids to a mixture of VLDL and HDL enhances unidirectional net 
transfer of cholesteryl ester from HDL to VLDL, without reciprocal transfer of triglycerides. 
This promotes the formation of very small HDL particles, probably equivalent to the pre-beta 
HDL, thought to be involved in the initial step of cholesterol efflux from cells into HDL. The 
ensemble of information suggests a   physiological role for the stimulation of CETP-mediated 
lipid transfer by products of lipolysis.  
 
Accelerated cholesteryl ester transfer between lipoproteins has been shown in Insulin 
dependent diabetics, perhaps reflecting accumulation of fatty acids in lipoproteins. The 
enrichment of lipoproteins with un-esterified cholesterol may also result in enhanced net 
cholesteryl ester transfer from HDL to VLDL. In general, the concentration of neutral lipids 
in the phospholipid surface of substrate particles appears to be an important determinant of 
lipid transfer activity. CETP-mediated lipid transfer between emulsions and LDL is enhanced 
by the presence of apolipoproteins, such as apolipoprotein A-I137. There do not appear to be 
specific protein co-factors influencing CETP activity. However, it has recently been shown 
that apolipoprotein A-II inhibits the production of smaller HDL by CETP 138.  
Also, Kinoshita et al.139 have recently shown, by apolipoprotein E supplementation of 
the plasma of an apolipoprotein E-deficient subject, that apolipoprotein E enhances lipid 
transfer from HDL to VLDL by enhancing the affinity of apolipoprotein E for VLDL. 
 
CETP GENE POLYMORPHISMS 
CETP GENE 
Human CETP gene is located in chromosome 16 (16q12-16q21) near the Lecithin-
cholesterol acyltransferase (LCAT) gene locus. (Figure 10). It spans over 25 kb, consisting of 
16 exons and 15 introns. The size of the exons ranges from 32 to 250 bp. Human CETP gene 
has a marked similarity to the plasma phospholipid transfer protein (PLTP) gene in the exon-
intron organization 140. Human PLTP transfers phospholipids between lipoproteins and has a 
20% sequence homology to human CETP. 
 
In the promoter region of the human CETP gene, sequences resembling a `TATA' box 
and an SP1-binding site were identified upstream from the translation start codon. The 
promoter region of human CETP gene contains a sequence resembling the binding site for the 
transcription factor CCAAT/enhancer-binding protein (C/EBP), which may be preserving 
CETP gene promoter activity 141. ARP-1 (Apolipoprotein regulatory protein-1) was shown to 
play a dichotomous role as both a transcriptional repressor and a transcriptional activator 
depending on the promoter context. 
 
 
 
 
 
Fig 10: CHOLESTERYL ESTER TRANSFER PROTEIN GENE LOCUS 
– Chr 16 q21 
 
  
 
 
 
CETP GENE POLYMORPHISMS AND CETP ACTIVITY 
 Several common restriction fragment length polymorphisms (RFLPs) have been 
reported in the human CETP gene, including TaqIA (intron 10), TaqIB (intron 1), StuI (exon 
12) , MspI (intron 8) and EcoNI (intron 9)22.  
TaqIB polymorphism (rs708272) is created by a silent base change affecting the 277th 
nucleotide in the first intron of the CETP gene22, and possesses restriction site for the 
endonuclease TaqI, resulting in two alleles B1 and B2.  Significant associations of the B1B1 
genotype with higher plasma CETP concentration and/or CETP activity and lower HDL-c 
levels were found in several studies.24-28 This association has been implicated to be 
population specific142, and highly influenced by environmental factors such as alcohol 
consumption and tobacco smoking 143. 
Isoleucine 405 to valine polymorphism (I405V) in exon 14 was also identified. This is 
a very common polymorphism, as the less-common allele is present in all populations 
examined and generally occurs at a frequency of over 25%. In multiple studies, those with the 
less-common 405V allele have lower CETP levels.144 
 
Recently, a new functional polymorphism, CETP -629A/C has been identified.145. The 
-629A allele was associated with lower CETP mass and higher HDL cholesterol levels than 
the   -629C allele. It was demonstrated that nuclear factors Sp1 and/or Sp3 suppress CETP 
promoter activity, whereas the binding of nuclear factors to the -629C allele has no effect on 
promoter expression. This is a unique polymorphism in the CETP gene promoter that may 
affect the promoter activity through the impaired binding of nuclear factors. 
A one-nucleotide substitution (G to A) in exon 15, which changes arginine (451) to 
glutamine, was also identified.146 Men heterozygous for the R451Q mutation showed 27% 
higher CETP activity than controls with normal genotype. 
 
Regarding the gene defects,147 a G-to-A mutation in the 5-splice donor site of intron 
14 was first identified in a Japanese patient with CETP deficiency. This defect was later 
identified in other Japanese CETP-deficient subjects and is associated with 
hyperalphalipoproteinemia (HALP).  Human CETP deficiency is associated with both a 
decreased rate of production of apoB and an increase in its rate of catabolism, consistent with 
an up-regulation of the LDL receptor in these subjects.148 Glueck et al. described families 
with familial HALP with hypobetalipoproteinemia, which was accompanied by longevity due 
to a low incidence of coronary heart disease 149. 
 
A missense mutation (442D: G) in exon 15 was later identified. Although the patients 
were heterozygous for this defect, they had a 3-fold increase in plasma HDL cholesterol and 
markedly decreased plasma CETP activity and mass. A nonsense CETP mutation in exon 10 
which causes a premature stop codon and another nonsense mutation in exon 6 (G181X) were 
also identified. The latter mutation causes a total deficiency of plasma CETP activity. 
Furthermore, a defect in the intron 10 splice donor site of CETP gene was found, which 
causes exon 10 skipping, resulting in abnormal downstream splice site selection. In the 
CETP-deficient patient with a heterozygous nonsense mutation (57Tyr→stop), the presence of 
a null allele in addition to the allele with the nonsense mutation was suggested. This patient 
was accompanied by a marked postprandial lipemia. Figure 11 summarizes the site of gene 
mutations and polymorphisms in the CETP gene reported so far. 
 
 
 
 FIGURE 11 : POLYMORPHISMS AND MUTATIONS IN HUMAN 
CETP GENE 
 
EFFECT OF CETP TaqIB POLYMORPHISM ON CETP ACTIVITY 
The Taq1B polymorphism is very frequent, with the heterozygous B1B2 state being 
the most common. The common B1 (presence of the TaqI restriction site at this polymorphic 
site) allele generally is associated with increase in CETP activity and decreased HDL level 
when compared to B2 allele. Due to its intronic location this polymorphism cannot be 
considered as a part of a functional regulatory site, but can be a marker for another functional 
site. Taq1B polymorphism has been found to be in strong linkage disequilibrium with the -
629C/A promoter mutation that occurs in a transcription factor binding site and affects 
Sp1/Sp3 binding 150. There is also a promoter VNTR located 1,946 bp upstream of the 
transcription start site that is linked to Taq1B and appears to have an independent effect on 
CETP and HDL levels151,152,153. Other promoter polymorphisms like −971G/A and −1337C/T 
have also been studied in combination with Taq1B and may also exert independent effects 
32,33. 
Subjects with genetic CETP deficiency have both elevated HDL cholesterol 
concentrations and decreased LDL cholesterol levels. A decrease in the catabolic rate of HDL 
apolipoproteins has also been reported. Although some of these effects are mediated through 
the actions of circulating CETP, CETP may also have an indirect effect on HDL and LDL by 
changing other potential lipoprotein receptors or apolipoprotein expressions. This view was 
supported by some studies indicating that CETP regulates the expression and secretion of an 
LDL receptor (LDL-R) and apolipoprotein A-I (apoA-I). 
Several species, including mice and rats, are naturally deficient in CETP.  Genetically 
engineered mice have proven to be valid models for the study of CETP function and its 
relation with atherosclerosis. Introduction of the human CETP gene into mice results in a 
dose-related reduction in HDL levels and a small increase in VLDL and LDL cholesterol and 
apolipoprotein B levels.131,154 . As a consequence, these animals have significantly more early 
atherosclerotic lesions in the proximal aorta than do control mice. Mice are relatively 
resistant to the development of diet-induced atherosclerosis and must clearly accomplish 
reverse cholesterol transport by pathways that do not involve CETP activity. In fact, in 
studies of bile salt and cholesterol-fed, C57-B16 mice, the introduction and expression of the 
simian CETP gene resulted in enhanced formation of fatty streak lesions compared with non-
expressing controls116. It was concluded that the enhancement of lesion development by 
CETP was secondary to a re-distribution of cholesterol from HDL to the VLDL/LDL 
fraction. These observations indicate the pro-atherogenic activities of CETP. 
 
 
 
OTHER DISEASES ASSOCIATED WITH CETP GENE POLYMORPHISMS  
As discussed above, a wide variety of cell types have been reported to secrete 
cholesteryl ester transfer activity, or protein, or to contain the CETP mRNA .Appreciable 
levels of cholesteryl ester transfer activity are present in seminal fluid and in cerebrospinal 
fluid. These findings strongly suggest that CETP influences lipid transfer processes in 
plasma, interstitial fluids, and within tissues and may play an important role in the 
development of various diseases such as atherosclerosis, diabetes mellitus, cholelithiasis, gall 
bladder cancer, age related macular degeneration, alzheimer’s dementia and metabolic 
syndrome. Several laboratories have reported investigations into the relationship between the 
CETP gene polymorphisms and diseases other than CHD. Durlach et al. showed that French 
male type 2 diabetics are at increased risk of coronary heart disease with the B1 allele, while 
there was no effect in females 155.   
 
CETP polymorphisms have been associated with increased risk for cholelithiasis. 
Juvonen et al. found that Finns with gall bladder disease have a higher risk of gallstones with 
the B1 allele when compared to those with B2 allele 156. Sergio et al showed that on Chilean 
women the CETP TaqIB polymorphism was significantly associated with an increased risk of 
gall bladder cancer157. Lopez-Rios et al showed  that the B1B1 genotype of the Taq1B CETP 
polymorphism is associated with more insulin resistance, higher post-oral glucose tolerance 
test  glucose levels and an increased risk of Type 2 diabetes mellitus in Canarian 
population.158. Ukkola et al. have reported that the B1B1 genotype of this mutation was 
associated with cerebrovascular disease in Finnish patients with type 2 diabetes mellitus 159. 
They also showed that individuals with the B2B2 genotype had a lower prevalence of signs 
of macroangiopathy. Meguro et al. found that Japanese type 2 diabetics have a higher 
likelihood of macroangiopathy with the B1B1 genotype than with the other genotypes 160. 
Radeau et al. showed that renal transplant recipients with the B1B1genotype were more likely 
to suffer CHD 161. 
 
Cholesteryl ester transfer protein gene is involved in central nervous system 
cholesterol homeostasis and has been associated with exceptional longevity162. The CETP 
gene was identified as a “longevity gene” in a sample of Ashkenazi Jews by Barzilai and 
colleagues162.. They showed that individuals with exceptional longevity and their offspring 
were significantly associated with larger HDL and LDL particle sizes and CETP I405V 
polymorphism. 
 
Sanders et al. showed that CETP I405V polymorphism is associated with slower 
memory decline and lower incident dementia and Alzheimer’s dementia (AD) risk.163. The 
single population-based case-control study reported that the I405V polymorphism was 
associated with AD risk in non-apolipoprotein E ε4 carriers.164 A Spanish study reported that 
ε4 carriers homozygous for the minor allele of the CETP -629C/A  polymorphism had a 
lower risk for AD than ε4 non-carriers but found no association between I405V and AD.165 
Alejandro et al. also suggested that the VV genotype of the I405V polymorphism of the 
CETP gene increases the risk of AD in the absence of the APOE4 allele 166.  
 
Cecile et al. found a significant association between the I405Vpolymorphism in the 
CETP gene with multiple features of the metabolic syndrome, i.e. the prevalence of 
abdominal obesity and prevalence of low HDL-cholesterol. For this polymorphism, the 
association with abdominal obesity was partly independent of the association with HDL-
cholesterol,  and vice versa.167. Anton et al. found that the rare B2 allele in the CETP gene 
significantly reduces the risk of the metabolic syndrome in subjects at high individual risk 
population 168. 
 
Chen et al found that rs3764261 polymorphism of CETP gene was associated with 
increased risk of age related macular degeneration. Because alleles near CETP gene are 
associated with decreased HDL levels in blood seem to increase the risk of age related 
macular degeneration.169 
Additionally one study demonstrated that CETP TaqIB polymorphism was associated 
with atrial fibrillation. Asselbergs et al. fond that CETP TaqIB polymorphism is significantly 
associated with the presence of AF in the context of micro- or macroalbuminuria, elevated C-
reactive protein, renal dysfunction, and ischemic heart disease. The underlying biological 
mechanism explaining the association between AF and the CETP TaqIB polymorphism 
remains unclear. A logical explanation would be that the widely acknowledged association 
between CETP gene variations (resulting in lower plasma CETP) and higher HDL cholesterol 
levels may prevent the initiation of (preclinical) atherosclerosis and subsequently the 
development of atrial fibrillation. This mechanism is very likely considering the modulating 
effect of ischemic heart disease on the association between CETP TaqIB polymorphism and 
AF in the present study.170 
These studies provide an indication that CETP gene polymorphisms may play a wider 
role in the lipid transport, and that its role may not be restricted to atherosclerosis. As to the 
precise relationship between CETP gene polymorphisms and other diseases, as far as the 
current research condition is concerned, there is still a long way to go before we can come to 
a conclusion, and much further research is still needed.   
 
 
 
  
 
 
 
 
AIM OF THE STUDY 
 
 
 
 
 
 
 
 
 
AIM OF THE STUDY 
 Disturbances in lipoprotein metabolism play a major role in atherogenesis, a disease 
characterized by difference in susceptibility among people in any given population. A strong 
inverse relation exists between plasma high-density lipoprotein level and the risk of coronary 
artery disease. The cardio-protective role of HDL is commonly explained by its function in 
the reverse cholesterol transport pathway.  
 Cholesteryl ester transfer protein, a hydrophobic glycoprotein plays an important role 
in HDL metabolism and in reverse cholesterol transport pathway. Available reports address 
on the variability of cholesteryl ester transfer protein activity among people in any given 
population. This variability is attributed to the various polymorphisms of cholesteryl ester 
transfer protein gene. 
 In this scenario, this in-depth study of coronary heart disease was performed with the 
current strategy of investigating the contribution of genes to coronary heart disease in the 
general population and is based on the hypothesis that some genetic loci for proteins that 
influence the susceptibility of an individual to coronary heart disease are polymorphic and 
that the products of different alleles at a given locus have different effects on the disease. If 
an allele at a polymorphic site in or near a candidate gene (gene whose product is suspected 
to be involved in the pathogenesis of atherosclerosis and development of coronary heart 
disease) can be shown to be associated with coronary heart disease in unrelated people, this 
would indicate that the allele is causally related to the development of coronary heart disease. 
 The candidate gene of this study is Cholesteryl ester transfer protein gene and the aim 
of the study is, 
• To determine the association of Cholesteryl ester transfer protein gene TaqIB 
polymorphism and the concerned Phenotype variation with Coronary artery disease.              
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MATERIALS AND METHODS 
STUDY POPULATION 
CASES 
The study sample comprised 146 unrelated Coronary Artery Disease patients (131 
male, 15 female) of Mean age 50.82 + 9.27 years. Inclusion criteria was more than 50% 
stenosis of at least one of the major coronary arteries. Patients with less obstruction were 
excluded. Patients with recent episode of Myocardial infarction (Less than 3 months) were 
also excluded. 
CONTROL SUBJECTS 
 Controls were recruited from out-patient department during their visit for non- cardiac 
cases. Age, Sex and other confounding factors like diabetes, hypertension, smoking, 
alcoholism were matched. For all diabetic controls, tread mill test was done. Only those with 
negative Tread Mill Test result were included in the study. 
METHODS 
Recumbent blood pressure and 12 lead ECG were recorded on each subject after a 
thirty minute rest on the couch. Height and weight were recorded and blood samples were 
collected by Venipuncture after fortnight fasting in two test tubes. One was collected into 
plain nonadditive tube and the other anticoagulated with EDTA. Plain tube was centrifuged at 
2000 rpm for 20 minutes and serum was utilised for lipid profile estimation. EDTA-
containing tube was centrifuged at 2000 rpm for 20 minutes to get the buffy coat for DNA 
extraction and plasma was used for estimation of CETP activity. 
 
BUFFY COAT SEPARATION 
Buffy coat was separated by centrifugation of EDTA tubes at 2000 revolutions per 
minute for 20 minutes. Buffy coat was transferred to 2mL eppendorf and was used for DNA 
extraction. Plasma separated was used for estimation of CETP activity. 
BIOCHEMICAL MARKERS 
Total cholesterol (TC), high density lipoprotein cholesterol (HDL-c), low density 
lipoprotein cholesterol (LDL-c) and triglyceride concentration (TGL) were determined 
enzymatically using kits and XL-300 auto analyzer at Centralized Biochemistry Laboratory at 
G.G.H, Chennai-3. 
DNA EXTRACTION BY MODIFIED HIGH SALT METHOD171 
RBC Lysis: 
• 400µL of buffy coat in a 2mL eppendorf is mixed with 1.6mL of 0.17M ammonium 
chloride and mixed by inversion until red cells are lysed for about 10 minutes 
• The cells are centrifuged at 4000rpm for 10minutes. 
• The white cell pellet is washed with 800µL of 0.17M ammonium chloride solution. The 
procedure is repeated till a clear white cell pellet is obtained. 
WBC Lysis 
• To the pellet 500 µL of TKM I solution is added. It is centrifuged at 10,000rpm for 
10minutes. 
 
 
Nuclear Lysis 
• Discard the supernatant. To the pellet add 500 µL of TKM II solution. To that add 300 µL 
of 6M  Nacl and 50 µL of 10% SDS. 
• Mix well (vortex), Centrifuge at 10,000 rpm for 10 minutes. 
• Save the supernatant. Transfer it to 1.5mL eppendorf. 
DNA Precipitation 
• To the supernatant double the volume of 100% ethanol is added. 
• The sample is stored at -20◦C for 1 hour. 
• Then it is centrifuged at 10,000 rpm for 20minutes at 4◦C in a refrigerated centrifuge. 
• The supernatant is discarded. To this 500 µL of 70% ethanol is added. The pellet is mixed 
and centrifuged at 10,000 rpm for 10minutes at 4◦C. 
• Supernatant is discarded and the pellet is air dried. 
Storage 
• To the pellet 30 µL of LTE buffer is added and the extracted DNA is stored at   -20◦C for 
future use. 
Identification 
• Extracted DNA was identified by 0.8% agarose gel electrophoresis with a constant 
voltage of 7V/ cm and comparison with a known molecular weight 1kb DNA 
ladder.Figure:12. 
 DNA EXTRACTION BY HIGH SALT METHOD 
  
Extracted DNA 
10000 bp 
•  Figure :12 shows, extracted DNA (lane 2 to 8) was tested on 0.8% agarose gel using 1kbp 
ladder (lane 1)   
 
•  Ladder shows 10000, 8000, 7000,6000, 5000, 4000, 3000, 2000  and 1000 bp fragments  
Concentration of extracted DNA 
• Concentration of extracted DNA was estimated using UV spectroscopy at 260nm.The 
absorbance at 260nm was 0.0204. Concentration was calculated using the formula: 1 OD 
is equivalent to 50µg/mL 
Conc. of DNA  = absorbance × 50µg/mL × dilution factor 
= 0.0204 × 50 × 100 
= 102 ng / µL 
• Purity of extracted DNA was assessed by 260/280 ratio and it was found to be > 1.7 
POLYMERASE CHAIN REACTION 
• 535 bp fragment of CETP gene was amplified using, 
• Forward primer – 5’-CACTAGCCC AGAGAGAGGAGTGCC–3’ 
• Reverse primer - 5’-CTGAGCCCAGCCGCACACTAAC–3’ 
Primer Reconstitution 
Primers are supplied in lyophilized form. Autoclaved distilled water is used to 
prepare 100 × concentrations i.e. 10times the molecular weight of primer is the 
volume of water required to prepare 100 × concentrations which is 100µmolar 
solution. 
• From this stock solution 10 × concentration is prepared as the working solution for PCR. 
 
MASTER MIX: 
• Genei Red Dye master mix in the following composition was used. 
• Master Mix consists of a unique inert red dye in addition to basic components necessary 
for PCR. 
• Reaction buffer consisted of Tris Hcl - 10mM at  pH 8.3 
                                                                       KCl - 50mM 
• MgCl2 - 1.5mM acts as catalyst. 
• dNTP’s were used in a concentration of 2.5mM each. 
• Taq polymerase in a concentration of 1.5 U. 
• Primers were used in a concentration of 9 pmol and DNA was used in a concentration of 
200ng. 
• PCR was carried out in a reaction volume of 25 µL with the following components; 
• PCR master mix –  12.5 µL 
• Forward primer –     0.9 µL 
• Reverse primer –     0.9 µL 
• DNA                 –    2 .0µL 
• Distilled water –     8.7 µL 
• Total                – 25 µL 
• Amplification was carried out in an Applied Biosystems thermal cycler with the 
following cycling conditions. 
 
Initial denaturation – 950 C -5min 
• 30 cycles of 
• Denaturation – 950C – 1 min 
• Annealing    -   650C – 1min 
• Extension  -      720C – 1min 
•  Final extension at 720C - 10 min. 
• Amplified product – amplicons of 535 bp was identified by 2% agarose gel 
electrophoresis by comparison with a known 100bp DNA ladder. Figure : 13. 
AGAROSE GEL ELECTROPHORESIS 
• PCR product is run on 2% agarose gel in a 30 mL agarose cast as follows: 0.6g of agarose 
is weighed and dissolved in 30mL of TAE buffer with a pH of 8.0. 
• It is microwaved for 60 secs, cooled and 1.5 µL of ethidium bromide (10mg/mL) is 
added. It is poured into a cast and allowed to solidify for 15 min before it is kept in the 
electrophoresis tank. 8 µL of PCR product is loaded onto wells and 4 µL of 100bp DNA 
ladder is loaded onto single well as a marker. It is electrophoresed at 8V/cm for 45min 
and visualized under UV illumination. 
 
 
 
 
 
POLYMERASE CHAIN REACTION 
 
 
 
 
• Figure shows the 535bp CETP gene PCR product (lane 2 to 8) on 2% agarose gel. 
  
• Lane1 shows 100bp DNA ladder – marker fragments include 1000, 900, 800,700, 600, 
500, 400, 300, 200, 100bp.
535 bp PCR product 
600 bp
500 bp 
100 bp 
  8       7        6     5      4      3       2      1
RESTRICTION DIGESTION OF PCR PRODUCTS 
CETP TaqIB polymorphism was detected by digestion of the PCR amplified product 
with the TaqI restriction enzyme (4 units for 2 hours) followed by size fractionation in 2% 
agarose gel electrophoresis. 
Principle of Taq1 enzyme digestion 
• B2 allele does not have the restriction site hence will yield a 535bp fragment. 
• B1 allele has the restriction site, hence gets cleaved to give 361bp and 174bp 
fragment. 
• Heterozygous individuals (B1B2) have 535bp, 361bp and 174bp fragments. 
• Analysis was done using a 100bp DNA ladder from Bangalore genei. 
Procedure 
• 16 µL of PCR product is aliquoted in an eppendorf and 4U of TaqI enzyme is added. 
The entire procedure is carried out in ice. The contents are mixed thoroughly. 
• The eppendorf is then placed in a 650C waterbath for 2 hours and reaction is stopped 
by adding 5 µL of gel loading dye and mixed thoroughly. 
• Restriction digested product is subjected to 2% agarose gel electrophoresis for 
genotyping. 
 
 
AGAROSE GEL ELECTROPHORESIS 
• 2% agarose gel electrophoresis is used for genotyping of CETP TaqIB polymorphism. 
• Restriction digested PCR amplicons were electrophoresed on 2% agarose gel  in a 60 mL 
agarose cast as follows: 1.2 g of agarose is weighed and dissolved in 60mL of TAE buffer 
with a pH of 8.0. 
• It is microwaved for 60 secs, cooled and 3 µL of ethidium bromide (10mg/mL) is added. 
It is poured into a cast and allowed to solidify for 15 min before it is kept in the 
electrophoresis tank. 
• 16 µL of PCR product is loaded onto wells and 4 µL of 100bp DNA ladder is loaded onto 
single well as a marker. It is electrophoresed at 8V/cm for 45min and visualized under 
UV illumination. Figure : 14. 
 
 
 
 
 
 
 
 
RESTRICTION DIGESTION PRODUCTS  
  
 
 
 
• Figure shows genotype analysis done on 2% agarose gel electrophoresis using 100bp DNA 
ladder (lane 1).  
 
• It shows the following fragments – 1000, 900, 800, 700, 600, 500, 400, 300, 200, 100bp. 
1000 bp
600 bp 
400 bp 
300 bp
200 bp
100 bp 
500 bp 
 535 bp 
 361 bp 
 174 bp 
Lane 1 – Ladder 
Lane 2,5 –B1B2 
Lane 3,4,6 –B1B1 
 Lane 7,8– B2B2
8 7 6 5 4 3 2 1
LIPID PROFILE 
The biochemical parameters undertaken for the study were determined using the 
following methodologies: 
Estimation of Plasma Total Cholesterol 
Method 
Cholesterol Esterase – Cholesterol Oxidase 
Kit used 
Liquixx  of  ERBA diagnostics Mannheim GmbH Ltd. 
Principle 
         Cholesterol Esterase 
Cholesterol Ester + H2O     Cholesterol+ Fatty acids 
                                       Cholesterol Oxidase 
Cholesterol + O2      Cholest-4-en-3-one + H2O2 
                                                                            Peroxidase 
2H2O2 + 4- Aminoantipyrine+ Phenol      Quinoneimine dye + 4H2O 
 
The concentration of cholesterol in the sample is directly proportional to the intensity of the 
red complex (Quinoneimine ), which is measured at 505nm. 
Reagent composition: 
Goods buffer (pH - 6.4)   100mmol/L 
Cholesterol Esterase       > 200U/L 
Cholesterol Oxidase       > 100U/L 
Peroxidase     > 3000 U/L 
4- Aminoantipyrine    0.3 mmol/L 
Phenol     5mmol/L 
Non - reactive stabilizers & surfactants 
Standard (Cholesterol 200mg/dL) 
Cholesterol      2g/L 
Procedure 
To 1 mL of the reconstituted reagent, 10 µL of plasma is added and reading is taken after 5 
mins of incubation at 37o C. 
Reference Values 
Cholesterol :  150-260 mg /dL 
Estimation of Plasma Triglyceride 
Method 
Enzymatic Colorimetric method 
Kit Used 
Liquixx  of  ERBA diagnostics Mannheim GmbH Ltd. 
 
 
 
Principle 
 Lipoprotein Lipase 
Triglycerides + H2O       Glycerol + Free Fatty acids 
Glycerol Kinase 
Glycerol + ATP     Glycerol -3- Phosphate + ADP 
  Glycerol -3- Phosphate Oxidase 
Glycerol -3- Phosphate + O2                              Dihydroxy acetone    
                             phosphate + H2O2 
               Peroxidase 
H2O2 + 4 Aminoantipyrine + 3,5-DHBS           Quinoneimine dye + 2H2O 
The intensity of chromogen (Quinoneimine) formed during the reaction is directly 
proportional to the triglyceride concentration in the sample and is measured at 505nm. 
Reagent composition: 
Pipes buffer (pH - 7.0)   40 mmol/L 
Lipoprotein Lipase    4000 U/L 
Glycerol Kinase    1500 U/L 
Glycerol -3- Phosphate Oxidase  4000 U/L 
Peroxidase     2200 U/L 
4- Aminoantipyrine    0.4 mmol/L 
ATP     2.0 mmol/L 
Magnesium (Mg+2)   2.5 mmol/L 
DHBS (3,5-Dichloro - 2 hydroxy 0.2 mmol/L 
benzene sulphonate) 
Standard (Triglycerides 200mg / dL) 
Glycerol  (Trig. Equivalent) 2g / L 
Procedure 
To 1 mL of the reconstituted reagent 10 µL of plasma is added and read at 505 nm 
after incubation at 37oC for 5minutes. 
Reference Range 
Males            60- 165 mg/dL 
Females         40- 140 mg/dL 
Estimation of HDL Cholesterol 
Method     
Modified polyvinyl sulfonic acid (PVS) and polyethylene-glycol-methyl ether  
(PEGME) coupled classic precipitation method 
Kit used         
 Erba XL System Packs 
Principle 
The assay is based on a modified polyvinyl sulfonic acid (PVS) and polyethylene-
glycol-methyl ether (PEGME) coupled classic precipitation method with the improvements in 
using optimized quantities of PVS/PEGME and selected detergents. LDL, VLDL and 
chylomicron (CM) react with PVS and PEGME and the reaction results in inaccessibility of  
LDL, VLDL and chylomicron (CM) by cholesterol oxidase (CHOD) and cholesterol esterase 
(CHER). The enzymes selectively react with HDL to produce hydrogen peroxide which 
yields a blue coloured complex upon oxidase condensation with TODB (N, N - Bis (4-
sulfobutyl)-3-methylaniline) and 4-aminoantipyrine (4-AA) in the presence of peroxidase 
(POD) . The intensity of chromogen (Quinone) formed during the reaction is directly 
proportional to the HDL-C concentration in the sample and is measured at 593 nm. 
                                                       PVS 
HDL + LDL + VLDL +CM                              HDL + ( LDL + VLDL +CM ) . PVS/PEGME     
               PEGME 
 
   CHER & CHOD 
HDL +  H2O  +  O2        Cholest-4-en-3-one + Fatty acid + H2O2 
 
                                              Peroxidase 
2H2O2  +  4-AA + TODB                                  Quinone + 5 H2O 
 
Reagent composition: 
Reagent 1 
MES buffer (pH - 6.5)    6.5 mmol 
TODB (N,N-Bis(4-sulfobutyl)-3-methylaniline)) 3 mmol 
Polyvinyl sulfonic acid (PVS)    50 mg/L 
Polyethylene-glycol-methyl ether    30 ml/L 
Magnesium chloride (MgCl2)    2 mmol 
EDTA 
Detergent 
 
Reagent 2 
MES buffer (pH - 6.5)    50 mmol 
Cholesterol  oxidase      20 kU/L 
Cholesterol esterase      5 kU/L 
Peroxidase       5 kU/L 
4- Aminoantipyrine      0.9 g/L 
Detergent      0.5% 
Calibrator 
HDL-C   60 mg/dL 
Procedure 
Reagent 1 & 2 are placed in the auto analyzer with the following assay parameters: 
Assay type : 2 point 
Primary wavelength nm : 600 
Secondary wavelength nm  : 700 
R-1 volume : 210 
R-2 volume  : 70 
Reaction direction : Increasing 
Sample volume  : 3 µL 
Calibration  : Straight 
Reference Values 
Adult male : 35.3 – 79.5 mg /dL 
Adult female : 42.0 – 88.0 mg / dL 
Estimation of LDL Cholesterol 
Method         
Modified polyvinyl sulfonic acid (PVS) and polyethylene-glycol-methyl ether 
(PEGME) coupled classic precipitation method 
 Kit used         
Erba XL System Packs 
Principle 
The assay is based on a modified polyvinyl sulfonic acid (PVS) and polyethylene-
glycol-methyl ether (PEGME) coupled classic precipitation method with the improvements in 
using optimized quantities of PVS/PEGME and selected detergents. LDL, VLDL and 
chylomicron (CM) react with PVS and PEGME and the reaction results in inaccessibility of  
LDL, VLDL and chylomicron (CM) by cholesterol oxidase (CHOD) and cholesterol esterase 
(CHER), whereas HDL reacts with the enzymes. Addition of reagent 2 containing a specific 
detergent releases LDL from the PVS/PEGME complex. The released LDL reacts with the 
enzymes to produce hydrogen peroxide which yields a blue colored complex upon oxidase 
condensation with TODB (N,N-Bis (4-sulfobutyl) -3-methylaniline) and 4-aminoantipyrine 
(4-AA) in the presence of peroxidase (POD) . The intensity of chromogen (Quinone) formed 
during the reaction is directly proportional to the HDL-C concentration in the sample and is 
measured at 593 nm. 
 
 
 
                                                        PVS 
HDL + LDL + VLDL +CM                              HDL + (LDL + VLDL +CM ) . PVS/PEGME     
               PEGME 
 
         CHER & CHOD 
HDL  +  H2O  +  O2        Cholest-4-en-3-one + Fatty acid + H2O2 
 
 
(LDL + VLDL +CM). PVS/PEGME  +  Detergent                                 LDL + 
     (VLDL +CM) . PVS/PEGME 
 
                                        CHER & CHOD 
LDL  +   H2O  +  O2        Cholest-4-en-3-one + Fatty acid + H2O2 
 
 
Peroxidase 
2H2O2  +   4-AA + TODB                                  Quinone + 5 H2O 
 
 
Reagent composition: 
Reagent 1 
MES buffer (pH - 6.5)    50 mmol 
Polyvinyl sulfonic acid (PVS)    50 mg/L 
Polyethylene-glycol-methyl ether    30 ml/L 
Magnesium chloride (MgCl2)    2 mmol 
EDTA 
Detergent 
Cholesterol  oxidase      20 kU/L 
Cholesterol esterase      5 kU/L 
Peroxidase       5 kU/L 
4- Aminoantipyrine      0.9 g/L 
 
Reagent 2 
MES buffer (pH - 6.5)    50 mmol 
EDTA 
Detergent       
TODB (N,N-Bis(4-sulfobutyl)-3-methylaniline)) 3 mmol 
 
LDL Calibrator 
LDL-C   107 mg/dL 
Procedure 
Reagent 1 & 2 are placed in the auto analyser with the following assay parameters: 
Assay type     : 2 point 
Primary wavelength (nm)     : 600 
Secondary wavelength (nm)    : 700 
Reagent-1 volume     : 210 
Reagent-2 volume      :          70 
Reaction direction     : Increasing 
Sample volume      :          3 µL 
Calibration      :  Straight                            
Expected Values 
Optimal    < 100 mg/dL  
Near/above optimal   100 - 129 mg/dL  
Boderline high   130 to 159 mg/dL 
High    160 to 189 mg/dL 
Very high    > 189 mg/dL 
 
VLDL Cholesterol 
VLDL-C was calculated by using the formula given below: 
VLDL-C     = TGL/5 
Estimation of Cholesteryl ester transfer protein activity: 
Cholesteryl ester transfer protein activity in plasma was measured by 
using Fluorometric assay kit. 
Principle 
The CETP Activity Assay Kit uses a donor molecule containing a fluorescent 
self-quenched neutral lipid that is transferred to an acceptor molecule in the presence 
of CETP172. CETP-mediated transfer of the fluorescent neutral lipid to the acceptor 
molecule results in an increase in fluorescence which is read in a fluorescence 
spectrometer at excitation wavelength of 465 nm and emission wavelength of 535 nm. 
Kit Contents: 
Components    Volume 
Donor molecule   1 ml 
Acceptor Molecule   1 ml 
CETP Assay Buffer (10X)  5 ml 
Positive Control (Rabbit Serum) 30 μL 
Preparation of Standard Curve: 
Standard curve is prepared by making serial dilutions of the donor molecule in 
isopropanol and subsequently recording the fluorescence intensity of each dilution, using 
isopropanol alone as a blank. 
1.  6 test tubes are labeled T0 to T5, each contains 0.2 ml of isopropanol and the tube 
labeled T5 contains an additional 0.2 ml of isopropanol. 
2.  2 μL of Donor Molecule is added to T5 and mixed well. 
3.  0.2 ml is transferred from T5 to T4 and mixed well. Then 0.2 ml is transferred 
from T4 to T3 and mixed.  Then 0.2 ml is transferred from T3 to T2 and mixed.  Then 0.2 ml 
is transferred from T2 to T1. The Donor Molecule solution contains 0.1 mM labeled lipids 
and thus the standard curve samples contain 0, 6.25, 12.5, 25, 50, 100 pmol donor molecule. 
4. The fluorescence intensity (Excitation = 465 nm; Emission = 535 nm) of the 
samples from T0 to T5 are read in a fluorescence spectrometer at excitation wavelength of 
465 nm and emission wavelength of 535 nm. 
5. The fluorescence intensity values of the standard curve are applied directly to our 
results to express activity of the plasma sample (pmoles/μL plasma/hr). 
Procedure 
For each reaction - 10 μL donor molecule, 10 μL   acceptor molecule, 20 μL 10X 
CETP assay buffer, 3 μL sample, distilled water to a total of 200 μL are added and incubated 
for 1 hour at 37°C.  A blank is prepared that contains water instead of CETP source. The 
samples are diluted to 500 μL with 1X CETP assay buffer and read in a fluorescence 
spectrometer at excitation wavelength of 465 nm and emission wavelength of 535 nm. A 
standard curve is used, according to the manufacturer’s guidelines, to derive the relation 
between fluorescence intensity and mass transfer. The activity is expressed in pmol/μL/hr. 
 
  
 
 
 
 
 
STATISTICAL ANALYSIS 
 
 
 
 
 
 
 
 
STATISTICAL ANALYSIS 
1. Allele frequencies were calculated by allele counting. 
2. Age, BMI, serum lipid levels were compared between control subjects and patients by 
Student’s t tes . 
3. Genotype frequency distribution between cases and controls were compared with a χ2 
test for  2*2 contingency table. 
4. Plasma Cholesteryl ester transfer protein activity was compared between control and 
cases by Student’s t test p<0.05 was considered significant. 
5. Plasma Cholesteryl ester transfer protein Activity, serum HDL-C and serum LDL-C 
were compared between CETP Taq1B genotypes by using one-way ANOVA and 
Student’s t test. 
6. Logistic regression analysis was performed to evaluate the interaction between human 
CETP Taq1B genotypes and other variables in relation to the prevalence of Coronary 
Artery Disease. Independent variables included in the analysis were age 
(quantitative), sex (male/female), smoking (yes/no), Alcoholism (Yes/No), 
Hypertension (Yes/No), Diabetes (Yes/No), Serum Levels of Cholesterol , 
Triglycerides (Quantitative). The analysis was executed by SAS Statistical program 
Version 6.10 for Macintosh. 
7. Plasma Cholesteryl ester transfer protein activity level, serum High Density 
Lipoprotein levels  and serum Low Density Lipoprotein levels were correlated by 
Pearson’s Correlation analysis. 
8. Relationship between the number of Coronary arteries and the Plasma Cholesteryl 
ester transfer protein activity was assessed by Spearman’s Rank Correlation analysis. 
  
 
 
 
 
 
 
 
 
RESULTS 
 
 
 
 
 
 
 
 
 
 
MASTER  CHART 
Table - 1 : LIPID LEVELS, BMI AND GENOTYPE OF CASES 
Sl. 
No 
Age 
(yr) Sex 
Angio 
Finding DM HYT SMK ALC 
WT 
(Kg) 
HT 
(m) 
BMI 
(kg/m2) 
CHOL 
(mg/dL) 
TGL 
(mg/dL) 
HDL 
(mg/dL) 
LDL 
(mg/dL) 
CETP Activity 
(pmol/μL/hr) 
CETP 
TaqIB 
Genotype 
1 44 M SVD No No Yes Yes 66 1.57 26.78 159 194.7 26.8 89.3 79.68 B1B2 
2 41 M TVD No Yes Yes No 71 1.64 26.48 175.3 180.5 44.8 90.4 94.47 B1B1 
3 40 M DVD Yes No No Yes 63 1.57 25.68 175.7 175.6 44.7 91.9 90.58 B1B1 
4 57 M SVD No No Yes No 68 1.62 25.89 167.9 116.9 50.1 90.4 78.94 B1B2 
5 59 F DVD No Yes No No 59 1.52 25.77 196.7 194.5 24.4 129.4 86.75 B1B1 
6 45 M TVD Yes No Yes No 78 1.68 27.67 197.6 197.8 23.5 130.5 114.57 B1B1 
7 46 M SVD No Yes No Yes 58 1.64 21.67 174.7 96.8 59.4 91.9 86.94 B1B2 
8 49 M SVD No Yes No No 72 1.71 24.78 188.5 185.7 22.8 124.6 99.2 B1B1 
9 40 M SVD No No Yes No 74 1.57 29.98 214 195.7 40.4 130.5 86.01 B1B2 
10 48 M DVD No Yes Yes Yes 81 1.59 31.99 161.8 180.8 44.1 77.5 104.29 B1B1 
11 44 M SVD No No Yes No 58 1.64 21.57 158.8 184.8 40.3 77.5 82.02 B1B2 
12 62 M SVD No Yes No Yes 64 1.7 21.99 215.5 193.6 38.3 134.5 91.73 B1B1 
13 50 M TVD Yes Yes Yes No 71 1.62 26.87 210.2 198.9 31.9 134.5 107.49 B1B1 
14 51 M DVD No Yes Yes No 61 1.7 21.24 146.2 88.8 39.5 84.9 64.4 B2B2 
15 59 F SVD No Yes No No 56 1.61 21.78 207.7 182.5 36.8 130.4 89.54 B1B2 
16 48 M TVD Yes Yes No Yes 80 1.58 32.01 203.7 196.9 29.9 130.4 99.58 B1B1 
Sl. 
No 
Age 
(yr) Sex 
Angio 
Finding DM HYT SMK ALC 
Wt. 
 (Kg) 
Ht. 
(m) 
BMI 
(kg/m2) 
CHOL 
(mg/dL) 
TGL 
(mg/dL) 
HDL 
(mg/dL) 
LDL 
(mg/dL) 
CETP Activity 
(pmol/μL/hr) 
CETP 
TaqIB 
Genotype 
17 40 M SVD No No Yes No 62 1.69 21.78 160.5 188.4 38.5 80.3 79.49 B1B2 
18 40 M SVD No Yes No No 71 1.54 29.87 150.4 98.5 46.4 80.3 102.64 B1B1 
19 51 M SVD Yes No Yes No 57 1.64 21.24 176.9 98.4 57.4 95.8 75.43 B1B2 
20 59 M SVD No Yes No No 59 1.72 20.01 209.8 189.4 37.4 130.5 61.81 B2B2 
21 49 M TVD Yes No Yes Yes 79 1.71 27.02 168.1 106.5 52.6 90.2 81.93 B1B2 
22 48 M SVD No Yes Yes Yes 54 1.53 22.87 168.7 188.4 36.7 90.3 86.02 B1B2 
23 58 M TVD No Yes No Yes 83 1.64 30.88 174.6 196.9 35.4 95.8 102.81 B1B1 
24 56 M SVD Yes No Yes No 60 1.63 22.66 176.6 189.5 34.2 100.5 89.93 B1B2 
25 54 M DVD Yes Yes No Yes 62 1.61 23.98 179.7 87.3 63.7 94.5 54.44 B2B2 
26 59 F SVD No Yes No No 72 1.71 24.56 160.3 197.8 26.5 90.2 106.69 B1B1 
27 59 M DVD No No Yes Yes 69 1.67 24.78 206.3 185.7 32.4 132.8 74.81 B1B2 
28 43 M SVD No Yes Yes No 61 1.6 23.67 216.4 90.2 64.9 129.5 53.45 B2B2 
29 47 M DVD Yes Yes No Yes 69 1.71 23.68 172.2 84.6 56.8 94.5 90.81 B1B2 
30 41 M SVD No Yes Yes No 70 1.65 25.77 170.3 196.4 34.6 92.4 92.82 B1B2 
31 40 M TVD No Yes No Yes 75 1.58 29.99 175.3 186.7 33.7 100.3 112.64 B1B1 
32 56 M DVD Yes Yes No Yes 73 1.62 27.68 162.2 193.5 36.7 82.8 83.64 B1B2 
33 58 M SVD No No Yes No 58 1.6 22.79 199.4 83.6 53.8 124.9 58.86 B2B2 
34 52 M DVD No Yes Yes No 61 1.58 24.57 184.8 188.4 36.8 106.3 78.63 B1B2 
35 40 M DVD No Yes No Yes 84 1.71 28.67 201.4 197.8 28.3 129.5 119.68 B1B1 
36 50 M TVD No No Yes Yes 76 1.75 24.67 175.9 84.8 59.2 95.7 85.49 B1B2 
Sl. 
 No 
Age 
(yr) Sex 
Angio 
Finding DM HYT SMK ALC 
Wt. 
 (Kg) 
Ht. 
(m) 
BMI 
(kg/m2) 
CHOL  
(mg/dL) 
TGL  
(mg/dL) 
HDL 
(mg/dL) 
LDL  
(mg/dL) 
CETP Activity 
(pmol/μL/hr) 
CETP  
TaqIB  
Genotype 
37 42 M SVD Yes Yes No No 64 1.64 23.68 201.9 184.6 51.4 109.6 61.82 B2B2 
38 38 M SVD No Yes Yes Yes 55 1.6 21.55 213.9 179.6 39.3 134.7 100.2 B1B2 
39 56 F TVD Yes Yes No No 77 1.62 29.46 206.8 190.8 31.8 132.8 108.69 B1B1 
40 55 M SVD No No Yes Yes 60 1.57 24.47 205.2 195.9 24.6 137.4 79.69 B1B2 
41 40 M TVD No No Yes Yes 60 1.66 21.79 152.5 78.5 51.9 80.9 78.84 B1B2 
42 39 M DVD Yes Yes No Yes 67 1.61 25.89 166.5 189.7 30.1 94.5 106.75 B1B1 
43 46 M DVD Yes Yes No No 69 1.64 25.66 200.6 130.6 50.2 120.3 86.06 B1B2 
44 62 M TVD No Yes Yes Yes 71 1.63 26.89 178.8 188.9 34.6 102.4 92.98 B1B1 
45 32 M SVD No No Yes No 67 1.67 23.99 156.1 96.8 49.9 82.8 104.41 B1B1 
46 50 M TVD Yes Yes No Yes 68 1.59 26.79 211.2 135.8 37.9 142.1 91.63 B1B2 
47 48 M DVD No No Yes Yes 62 1.55 25.87 183.6 188.3 25.6 116.3 108.64 B1B1 
48 57 M DVD No No Yes No 60 1.56 24.57 249.4 184.6 54.7 153.8 75.93 B1B2 
49 52 M TVD Yes Yes No Yes 76 1.6 29.68 169.3 184.7 22.7 105.7 108.59 B1B1 
50 59 M TVD No Yes No Yes 66 1.67 23.55 194.6 186.9 46.3 106.9 86.32 B1B2 
51 51 M DVD Yes No Yes Yes 73 1.72 24.57 209.6 195.4 31.8 134.7 114.68 B1B1 
52 49 M SVD No No Yes Yes 57 1.63 21.46 211.2 193.7 52.7 115.8 61.91 B2B2 
53 59 M DVD Yes Yes No Yes 68 1.65 24.88 169.3 74.7 50.1 100.3 74.81 B1B2 
54 48 M TVD No No Yes Yes 74 1.67 26.43 208.1 185.7 29.6 137.4 97.59 B1B1 
55 64 F SVD Yes Yes No No 63 1.63 23.54 151.8 80.6 39.2 92.5 83.24 B1B2 
56 50 M DVD No No Yes Yes 79 1.69 27.71 179.2 180.5 38.9 100.2 85.39 B1B2 
Sl.  
No 
Age 
(yr) Sex 
Angio  
Finding DM HYT SMK ALC 
Wt.  
(Kg) 
Ht. 
(m) 
BMI 
(kg/m2) 
CHOL  
(mg/dL) 
TGL  
(mg/dL) 
HDL  
(mg/dL) 
LDL  
(mg/dL) 
CETP 
Activity 
(pmol/μL/hr) 
CETP  
TaqIB  
Genotype 
57 56 M DVD No Yes Yes No 68 1.62 25.81 150.7 88.4 48.1 80.9 108.92 B1B1 
58 61 M SVD Yes No Yes No 62 1.66 22.54 168.9 187.8 43.1 84.2 63.81 B2B2 
59 44 M TVD No No Yes No 73 1.74 24.21 241.9 96.9 59.1 159.4 60.34 B1B2 
60 41 M TVD Yes No No Yes 81 1.64 29.98 191.5 185.3 30.1 120.3 104.69 B1B1 
61 41 M DVD No Yes Yes No 76 1.69 26.53 167.8 189.8 33.4 92.4 93.68 B1B2 
62 62 M SVD No No Yes No 73 1.72 24.72 208.7 154.7 39.9 133.9 64.68 B2B2 
63 47 M TVD No No Yes No 72 1.65 26.54 167.7 74.8 60.1 88.6 69.47 B1B2 
64 42 M SVD Yes No Yes No 78 1.71 26.84 217.2 191.2 32.9 142.1 99.19 B1B1 
65 47 F SVD No Yes No No 56 1.58 22.34 172.8 183.7 38.7 93.4 83.79 B1B2 
66 54 M TVD No No Yes Yes 74 1.67 26.65 161.7 96.3 49.1 89.3 116.4 B1B1 
67 60 M DVD No No Yes No 73 1.65 26.88 209.9 190.5 35.2 132.6 87.93 B1B2 
68 59 M TVD No Yes Yes No 68 1.57 27.74 222.2 199.2 24.6 153.8 108.89 B1B1 
69 53 M DVD No No No Yes 73 1.57 29.71 171.6 190.7 34.9 94.6 86.91 B1B2 
70 43 M TVD No No Yes No 72 1.67 25.82 183.4 193.2 23.9 116.9 114.9 B1B1 
71 42 M TVD No No Yes Yes 80 1.64 29.81 209.3 175.4 40.1 130.1 69.02 B1B2 
72 34 M SVD Yes Yes No No 57 1.68 20.24 208.5 180.6 38.7 129.7 69.91 B2B2 
73 39 M TVD No No Yes Yes 80 1.68 28.53 185.3 198.3 31.3 110.3 102.69 B1B1 
74 40 M SVD No No Yes No 73 1.66 26.41 189.3 165.6 58.7 93.5 69.49 B1B2 
75 56 M SVD No Yes No No 57 1.63 21.58 169.42 164.6 39.7 92.8 71.92 B2B2 
76 57 M DVD Yes No Yes Yes 78 1.65 28.75 253.2 189.4 56.5 154.8 79.69 B1B2 
Sl. 
 No 
Age 
(yr) Sex 
Angio  
Finding DM HYT SMK ALC 
Wt. 
(Kg) 
Ht. 
(m) 
BMI 
(kg/m2) 
CHOL 
(mg/dL) 
TGL 
(mg/dL) 
HDL 
(mg/dL) 
LDL 
(mg/dL) 
CETP Activity 
(pmol/μL/hr) 
CETP 
TaqIB  
Genotype 
77 59 F TVD No Yes No No 75 1.64 28.02 185.9 189.7 31.5 112.5 98.26 B1B1 
78 64 M SVD No No Yes No 64 1.65 23.53 136.3 184.8 40.5 54.8 64.57 B2B2 
79 36 M TVD Yes No No Yes 69 1.67 24.65 143 74.7 34.8 89.3 78.91 B1B2 
80 49 M DVD No No Yes Yes 82 1.66 29.83 212 194.6 36.4 132.7 64.91 B2B2 
81 68 M DVD No No Yes Yes 74 1.6 28.93 219.9 190.7 34.2 143.6 95.68 B1B2 
82 57 F TVD Yes Yes No No 73 1.62 27.72 156.9 89.6 34.8 100.2 115.49 B1B1 
83 62 M DVD No No Yes No 78 1.62 29.83 168.7 190.4 37.2 89.4 84.64 B1B2 
84 51 M TVD No Yes No No 76 1.65 27.81 231.7 184.3 31.4 159.4 109.68 B1B1 
85 65 M DVD No No Yes Yes 74 1.64 27.51 202.6 190.5 34.6 125.9 95.83 B1B2 
86 53 M SVD No No Yes No 73 1.71 24.92 123.5 83.9 39.8 62.9 70.1 B2B2 
87 59 M SVD Yes No No No 57 1.66 20.61 169.4 196.8 35.7 90.3 94.39 B1B2 
88 56 M DVD No No Yes Yes 75 1.64 27.9 138.4 196.9 38.7 56.3 69.54 B2B2 
89 68 F DVD Yes Yes No No 80 1.65 29.51 164.2 177.5 36.8 87.9 89.65 B1B2 
90 59 M SVD No No No Yes 55 1.63 20.71 212.7 154 42.1 135.8 65.84 B2B2 
91 39 M DVD No No Yes Yes 73 1.63 27.61 226.3 197.6 36.9 145.9 93.01 B1B2 
92 53 M TVD No Yes Yes No 78 1.62 29.84 167.1 189.7 32.8 92.4 104.69 B1B1 
93 63 M SVD Yes No Yes No 52 1.55 21.51 160.5 151.4 35.7 90.5 89.76 B1B2 
94 66 M TVD No Yes Yes Yes 57 1.54 23.96 169.7 192.4 38.6 88.6 110.6 B1B1 
95 63 M SVD No No Yes No 62 1.65 22.65 151.7 198.9 43.2 64.7 68.53 B2B2 
Sl. 
 No 
Age 
(yr) Sex 
Angio 
Finding DM HYT SMK ALC 
Wt 
 (Kg) 
Ht. 
(m) 
BMI 
 (kg/m2) 
CHOL 
(mg/dL) 
TGL  
(mg/dL) 
HDL 
(mg/dL) 
LDL 
(mg/dL) 
CETP Activity 
(pmol/μL/hr) 
CETP 
TaqIB 
Genotype 
96 54 M DVD Yes No No Yes 82 1.66 29.72 153.9 172.5 34.9 80.49 94.92 B1B2 
97 63 M TVD Yes No No No 69 1.64 25.83 192.2 175.3 29.7 123.4 122.89 B1B1 
98 59 M SVD No Yes Yes No 66 1.69 22.94 160.6 164.6 38.9 84.8 94.71 B1B2 
99 50 M TVD No No Yes No 70 1.62 26.83 200.2 196.4 24.3 132.6 108.89 B1B1 
100 66 M TVD Yes Yes No No 82 1.66 29.83 206.9 111.9 35.7 144.8 89.76 B1B2 
101 38 M DVD No Yes Yes No 79 1.62 29.97 154.5 141.6 34.6 87.6 98.78 B1B2 
102 61 M SVD Yes No Yes No 79 1.61 30.64 157.8 189.8 21.2 94.6 110.68 B1B1 
103 49 M TVD No No Yes Yes 65 1.66 23.46 191.6 175.4 22.4 130.1 101.61 B1B1 
104 36 M SVD No No Yes Yes 58 1.64 21.42 193.3 193.5 35.8 114.8 94.97 B1B2 
105 67 M TVD Yes No No Yes 69 1.67 24.67 186.9 164.7 36.5 113.5 110.67 B1B1 
106 56 M DVD Yes No Yes No 76 1.6 29.65 153.8 76.9 55.1 79.3 68.97 B1B2 
107 67 F TVD Yes Yes No No 66 1.66 23.86 198.5 85.6 22.6 154.8 105.4 B1B1 
108 60 M DVD Yes No No Yes 64 1.58 25.74 162.5 193.5 26.1 93.7 96.03 B1B2 
109 51 M DVD No Yes Yes No 63 1.59 24.87 162.1 152.4 27.2 100.4 96.04 B1B2 
110 67 M TVD Yes No Yes Yes 70 1.68 24.76 158.4 154.7 34.2 89.3 110.53 B1B1 
111 57 M TVD No No No Yes 74 1.55 30.75 180.6 183.5 35.3 104.6 93.92 B1B2 
112 53 M SVD Yes No Yes No 61 1.62 23.41 186.6 126.4 36.9 120.4 94.96 B1B2 
113 41 M TVD No Yes No Yes 64 1.65 23.53 221.3 197.8 34.1 143.6 98.97 B1B1 
114 44 M SVD Yes No Yes No 53 1.62 20.31 160 162.4 32.6 91.9 93.76 B1B2 
Sl.  
No 
Age  
(yr) Sex 
Angio  
Finding DM HYT SMK ALC 
Wt. 
 (Kg) 
Ht. 
 (m) 
BMI  
(kg/m2) 
CHOL  
(mg/dL) 
TGL  
(mg/dL) 
HDL  
(mg/dL) 
LDL  
(mg/dL) 
CETP Activity 
(pmol/μL/hr) 
CETP 
TaqIB  
Genotype 
115 59 M SVD No No Yes No 61 1.69 21.42 208.1 185.8 36.4 130.5 94.02 B1B2 
116 43 M TVD No No Yes Yes 80 1.64 29.56 158.9 88.8 47.7 89.4 110.09 B1B1 
117 50 M TVD No Yes No No 75 1.61 28.75 196.9 195.7 27.9 125.9 109.97 B1B1 
118 56 F DVD No Yes No No 79 1.62 29.97 139.7 189.4 40.3 57.5 86.03 B1B2 
119 41 M SVD No No Yes No 49 1.56 20.22 179.2 169.3 36.8 104.54 94.96 B1B2 
120 53 M TVD No Yes No Yes 70 1.61 26.98 162.5 183.8 31.4 90.3 110.48 B1B1 
121 46 M DVD Yes No Yes No 80 1.63 29.94 116.7 90.4 44.2 50.4 64.73 B2B2 
122 34 M SVD No No Yes No 58 1.59 22.86 168.2 184.6 26.9 100.4 97.92 B1B2 
123 67 F TVD No Yes No No 82 1.64 30.46 203 197.1 31.7 127.9 118.58 B1B1 
124 58 F DVD Yes No No No 79 1.6 30.76 168.1 179.7 27.9 100.3 97.95 B1B2 
125 34 M SVD No No Yes Yes 53 1.61 20.55 151.5 93.4 41.9 86.9 56.46 B2B2 
126 64 M SVD No Yes Yes No 67 1.65 24.75 119.3 91.5 41.2 55.8 84.83 B1B2 
127 34 M TVD No No Yes Yes 82 1.66 29.75 221.9 187.9 34.4 145.9 98.48 B1B1 
128 54 M DVD Yes No Yes Yes 80 1.64 29.64 183.5 192.4 40.8 100.2 85.64 B1B2 
129 40 M SVD No No Yes No 63 1.59 24.88 120.1 103.6 37.1 58.3 89.54 B1B2 
130 49 M TVD No No Yes Yes 77 1.6 29.98 189.9 196.4 46.1 100.5 84.64 B1B1 
131 39 M TVD No No Yes Yes 63 1.64 23.35 155 84.8 54.5 80.49 90.57 B1B1 
132 64 F SVD Yes No No No 62 1.71 21.08 209.7 190.3 37.2 130.4 87.96 B1B2 
133 48 M TVD No No No Yes 75 1.57 30.56 151.8 88.5 45.3 84.8 110.57 B1B1 
Sl.  
No 
Age 
 (yr) Sex 
Angio 
Finding DM HYT SMK ALC 
Wt.  
(Kg) 
Ht. 
(m) 
BMI  
(kg/m2) 
CHOL  
(mg/dL) 
TGL  
(mg/dL) 
HDL  
(mg/dL) 
LDL  
(mg/dL) 
CETP Activity 
(pmol/μL/hr) 
CETP 
TaqIB  
Genotype 
134 45 M TVD No No Yes Yes 66 1.67 23.56 148.3 83.7 51.8 75.8 75.74 B1B2 
135 39 M SVD No No Yes No 70 1.71 23.98 218.4 197.6 30.1 144.8 89.91 B1B1 
136 64 M SVD Yes Yes No No 69 1.68 24.42 138.2 147.9 40.1 64.5 86.86 B1B2 
137 66 M TVD No No Yes Yes 76 1.57 30.94 173.4 88.4 54.1 97.6 109.59 B1B1 
138 39 M DVD Yes No No No 79 1.66 28.57 188.2 192.5 37.9 107.8 94.83 B1B2 
139 41 M SVD No Yes No No 55 1.63 20.87 222.2 192.6 36.9 142.8 96.64 B1B2 
140 42 M TVD No No Yes Yes 82 1.65 29.96 193.1 193.5 35.6 114.8 91.89 B1B1 
141 41 M SVD No No No Yes 82 1.69 28.75 167.5 180.6 40.5 86.9 83.03 B1B2 
142 35 F DVD Yes Yes No No 70 1.56 28.85 160.4 83.5 50.4 89.3 104.89 B1B1 
143 48 M SVD Yes No No No 66 1.54 27.65 157.3 195.8 38.4 75.7 96.94 B1B2 
144 52 M TVD No No Yes Yes 76 1.65 27.84 164.2 197.8 26.9 93.7 109.99 B1B1 
145 46 M SVD No Yes No No 68 1.65 24.86 146.4 186.4 40.4 64.7 86.75 B1B2 
146 41 M DVD No No Yes Yes 74 1.66 26.97 188.5 193.6 25.4 120.4 110.83 B1B1 
TABLE 3: CHARACTERISTICS OF PATIENTS WITH CAD AND OF CONTROL SUBJECTS 
Variables Case Control P value 
Age 50.82 + 9.3 50.81 + 8.8 0.99 –NS 
Sex       male 131 (89.7%) 128 (88.3%) 
0.69 –NS 
Female 15 (10.3%) 17 (11.7%) 
DM 48 (51.1%) 46 (48.9%) 0.83 –NS 
HT 61 (48.8%) 64 (51.2%) 0.69 –NS 
DM+HT 23 (15.8%) 20 (13.8%) 0.61 – NS 
SMK 87 (54%) 74 (46%) 0.14 –NS 
ALC 66 (52.8%) 59 (47.2%) 0.44 –NS 
BMI 25.36 +3.25 24.99 + 3.14 0.27 –NS 
Total cholesterol 180.9 +26.7 159.9 +23.2 0.000 –S 
Triglycerides 161.6 +42.8 128 +27.6 0.000 –S 
High Density lipoprotein 38.5 +9.7 48.2+9.9 0.000 –S 
Low Density lipoprotein 106 +25.3 82.1+25.1 0.000-S 
TABLE 4:  GENOTYPE DISTRIBUTION OF HUMAN CETP GENE 
 
Genotype Control Case P value 
B1B1 31 (21.4%) 56 (38.4%) 
Chi sq = 19.18 
 
p= 0.000 – S 
 
B1B2 67 (46.2%) 71 (48.6%) 
B2B2 47 (32.4%) 19 (13%) 
  
FIGURE 15:  GENOTYPE DISTRIBUTION OF HUMAN CETP GENE 
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TABLE 5:  COMPARISON OF CETP ACTIVITY AMONG CONTROLS AND CASE 
 
 
 
Variable Control Case P value 
CETP ACTIVITY 
(pmol/μL/hr) 65.23 + 2.23 90.72+15.83 0.000 –S 
  
FIGURE 16: COMPARISON OF CETP ACTIVITY AMONG CONTROLS AND CASES 
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TABLE 6: RELATIONSHIP BETWEEN CETP ACTIVITY AND GENOTYPES 
 
Variable B1B1 Genotype B1B2 Genotype B2B2 Genotype P value 
CETP Activity 
(pmol/μL/hr) 97.09 74.53 59.1 0.000-S 
 
 
  
FIGURE 17 : RELATIONSHIP BETWEEN CETP ACTIVITY AND GENOTYPES 
0
10
20
30
40
50
60
70
80
90
100
CETP ACTIVITY
B1B1
B1B2
B2B2
 
 
      
 
  TABLE 7: RELATIONSHIP BETWEEN HDL-C, LDL-C AND GENOTYPES 
 
 
 
 
 
 
Variable B1B1 B1B2 B2B2 P Value 
HDL-C 37 44.6 50.2 0.0002 
LDL-C 104.9 91.9 82.3 0.0004 
  
   FIGURE 18 : RELATIONSHIP BETWEEN HDL-C, LDL-C AND GENOTYPES 
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 TABLE 8 : CORRELATION BETWEEN HIGH DENSITY LIPOPROTEIN AND CETP ACTIVITY 
**Correlation is significant at the 0.01 level (2-tailed). 
 
 
 
Group 
  
 
HDL 
 
 
CETP ACTIVITY 
Control 
HDL                                   Pearson correlation 
                                           Sig. (2-tailed)  
                                            N 
                  1 
 
                145 
 
                 -.716** 
                   .000 
                    145 
CETP ACTIVITY              Pearson correlation 
                                            Sig. (2-tailed)  
                                            N 
          -.716** 
             .000 
              145 
 
                        1       
 
                     145 
Case 
  HDL                                 Pearson correlation 
                                           Sig. (2-tailed)  
                                           N 
                  1 
 
               146 
                 -.544** 
                   .000 
                    146 
CETP ACTIVITY              Pearson correlation 
                                           Sig. (2-tailed)  
                                           N 
          -.544** 
           .000 
            146 
 
                        1       
 
                     146 
TABLE 9 : CORRELATION BETWEEN LOW DENSITY LIPOPROTEIN AND CETP ACTIVITY 
**Correlation is significant at the 0.01 level (2-tailed). 
 
 
 
Group 
  
 
LDL 
 
 
CETP ACTIVITY 
Control 
LDL                                   Pearson correlation 
                                           Sig. (2-tailed)  
                                            N 
                 1 
 
             145 
 
                    .443**
                    .000 
                     145 
CETP ACTIVITY              Pearson correlation 
                                            Sig. (2-tailed)  
                                            N 
            .443**
             .000 
              145 
 
                         1      
 
                     145 
Case 
  LDL                                 Pearson correlation 
                                           Sig. (2-tailed)  
                                           N 
                  1 
 
              146 
                    .204**
                    .014 
                     146 
CETP ACTIVITY              Pearson correlation 
                                           Sig. (2-tailed)  
                                           N 
            .204**
            .014 
             146 
 
                          1     
 
                     146 
TABLE 10: CORRELATION BETWEEN CETP ACTIVITY AND NUMBER OF VESSELS STENOSED  
 
 
 
 
 
 CETP Activity (pmol/µL/1hr) Angio Finding 
Kendall's tau_b CETP Activity 
(pmol/µL/1hr) 
Correlation Coefficient 1.000 .325(**)
  Sig. (2-tailed)   . .000
  N 291 146
   Angio Finding Correlation Coefficient .325(**) 1.000
  Sig. (2-tailed)      .000 .
  N 146 146
Spearman's rho CETP Activity 
(pmol/µL/1hr) 
Correlation Coefficient 1.000 .417(**)
  Sig. (2-tailed)         . .000
                               
  
 
                     ** Correlation is significant at the 0.01 level (2- tailed). 
N    291 146
   Angio Finding Correlation Coefficient .417(**) 1.000
  Sig. (2-tailed)         .000 .
  N    146 146
  
 
TABLE 11: UNIVARIATE ANALYSIS 
GENOTYPE CONTROLS (n) CASES (n) ODDS RATIO P VALUE 
B1B1 31 56 3.1 (1.8 - 5.4)  0.000 
B1B2 67 71 2.3 (1.3 – 3.8) 0.002 
B2B2 47 19 1.0 
  
                                     TABLE 12: MULTIVARIATE LOGISTIC REGRESSION ANALYSIS 
VARIABLES B S.E. WALD Sig. Exp (B) 
95% CI 
UPPER LOWER 
AGE 0.017 0.022 0.619 0.432 1.017 0.975 1.061 
SEX -0.664 0.746 0.791 0.374 0.515 0.119 2.222 
SMOKING 0.814 0.558 2.126 0.145 2.257 0.756 6.739 
ALCOHOLISM -0.188 0.443 0.179 0.672 0.829 0.348 1.977 
DIABETES 0.422 0.666 0.400 0.527 1.525 0.413 5.628 
HYPERTENSION -0.092 0.592 0.024 0.877 0.912 0.286 2.909 
DIABETES+ HYPERTENSION 0.254 0.876 0.084 0.772 1.289 0.232 7.174 
BMI -0.028 0.062 0.207 0.649 0.972 0.862 1.097 
TOATL HOLESTEROL 0.025 0.008 7.811 0.003 1.025 1.009 1.042 
TRIGLYCERIDES 0.011 0.006 3.297 0.069 1.011 0.999 1.023 
HDL -0.072 0.028 6.604 0.010 1.075 1.017 1.136 
LDL 0.237 0.557 3.123 0.000 1.534 1.096 2.167 
CETP ACTIVITY 0.197 0.726 4.505 0.000 1.218 1.156 1.283 
CETP POLYMORPHISM 0.844 0.674 8.802 0.000 2.040 1.011 3.150 
CONSTANT -2.081 1.140 4.075 0.014 0.103   
  
RESULTS 
 
a. Table 3 shows Age, Sex, BMI, High Density Lipoprotein levels, Low Density 
Lipoprotein levels and conventional risk factor distribution among patients and 
control subjects. We obtained a non-significant p value with respect to all the 
confounding variables like age, sex, BMI, history of diabetes, hypertension, smoking, 
alcoholism. There was a significant difference in the Total cholesterol level (high in 
cases - 180.9 +26.7, low in controls - 159.9 +23.2), Triglycerides level (high in cases -
161.6 +42.8, low in controls - 128 +27.6), Low Density lipoprotein level (high in 
cases - 106 +25.3, low in controls - 82.1+25.1) and High Density Lipoprotein level 
(low in cases - 38.5 +9.7, high in controls - 48.2+9.9). 
b. Table 4 shows Genotype distribution of human CETP gene in patients with CAD and 
control subjects. The Allele frequencies were B1B1 = 87, B1B2 =138 and B2B2 = 66. 
This was found to be in Hardy Weinberg equilibrium.  
• B1B1 genotype was more frequent among cases (38.4%) when compared to controls 
(21.4%). In contrast B2B2 was more common among controls (32.4%) when 
compared to cases (13%).  There was a significant difference in the distribution of 
B1B2 genotype also between cases (48.6%) and controls (46.2%). P value is 0.000.  
• Table 5 shows the comparison of CETP activity among cases and controls. 
Significantly high CETP activity could be observed among cases (90.72+ 15.83) 
when compared to controls (65.23 + 12.23). 
  
• Table 6 shows the difference in CETP activity between B1B1 genotype, B1B2 
genotype and B2B2 genotype. The activity was significantly higher among B1B1 
genotype (97.09 pmol/μL/hr; p = 0.000 vs B2B2) and B1B2 genotype individuals 
(74.53 pmol/μL/hr; p = 0.000 vs B2B2) when compared to B2B2 genotype 
individuals (59.1).  
• Table 7 shows the difference in HDL-C and LDL-C levels between B1B1 genotype, 
B1B2 genotype and B2B2 genotype. The HDL-C was significantly lower among 
B1B1 genotype (37 mg/dL; p value = 0.000 vs B2B2) and B1B2 genotype individuals 
(44.6 mg/dL; P = 0.001 vs B2B2) when compared to B2B2 genotype individuals (50.2 
mg/dL). The LDL-C was significantly higher among B1B1 genotype (104.9 mg/dL; p 
value = 0.000 vs B2B2) and B1B2 genotype individuals (91.9 mg/dL; P = 0.05 vs 
B2B2) when compared to B2B2 genotype individuals (82.3 mg/dL). 
• Table 8 shows the correlation between High Density Lipoprotein levels and CETP 
Activity. There was a strong negative correlation between High Density Lipoprotein 
levels and CETP activity among controls and cases. 
• Table 9 shows the correlation between Low Density Lipoprotein levels and CETP 
Activity. There was a strong positive correlation between Low Density Lipoprotein 
levels and CETP activity among controls and cases. 
• Table 10 shows the correlation between CETP activity and the number of vessels 
stenosed. Single vessel disease was ranked 1, double vessel disease 2 , Triple Vessel 
disease 3 . There was a positive correlation between activity and the rank. i.e as the 
activity increased number of vessels affected increased. 
• Table 11 shows the Odds ratio calculation on Univariate analysis to evaluate the risk 
of atherosclerosis among B1B1 genotype individuals (Odds ratio is 3.1; 95% CI – 1.8 
to 5.4) and B1B2 genotype individuals (Odds ratio is 2.3; 95% CI – 1.3 to 3.8). 
• On multivariate analysis (Table 12), we obtained a significant negative correlation 
coefficient for HDL levels as expected i.e., an increase in the HDL levels decreased 
the possible occurrence of atherosclerosis, whereas there was a positive correlation 
coefficient for CETP B1B1genotype and plasma CETP activity i.e., presence of CETP 
B1B1 genotype and an increase in the CETP activity would increase the possibility of 
atherosclerosis. The standardized correlation coefficient for CETP B1B1 genotype 
i.e., the odds ratio was 2.04 (95% CI 1.011 – 3.150).  
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DISCUSSION 
Both genetic and environmental factors play an important role in the pathogenesis of 
CAD in humans. These factors may vary depending on race and ethnic group. The 
susceptibility to CAD is a complex trait171. 
Worldwide studies have been done correlating the genetic polymorphisms of CETP 
with risk for CAD173,174. In view of this a comprehensive population based study was 
performed to determine the association of CETP gene TaqIB polymorphism and its 
associated CETP activity with Coronary atherosclerosis. 
  The three human CETP genotypes and the phenotypes were determined in 146 
patients with CAD confirmed by angiography and 145 control subjects. The insignificant p 
value with respect to all the confounding variables like age, sex, BMI, history of diabetes, 
hypertension, smoking, alcoholism showed that the cases and control groups had been 
perfectly matched. The significantly low High Density Lipoprotein level (38.5 +9.7), high 
Low Density Lipoprotein (106 +25.3) in cases    re-emphasizes the fact that HDL is 
protective and LDL causes atherogenesis. 
  When genotype analysis was performed, distribution of B1B1 genotype was 
significantly higher among cases (56 (38.4%)) when compared to controls (31 (21.4%)). P 
value was 0.000 showing that it is significant. This indicates that B1B1 genotype is an 
independent risk factor for atherosclerosis. There was a significant difference in the 
distribution of B1B2 genotype also between cases and controls .P value was 0.002. 
  The evidence available showed that there is a significantly high CETP activity among 
cases (90.72+15.83) when compared to controls (65.23 + 12.23). P value was 0.000. This 
shows that high CETP activity is an independent risk factor for atherosclerosis.  
  When the CETP activity was compared between CETP TaqIB genotypes there was a 
significantly high CETP activity among B1B1 genotypic individuals (97.09 pmol/μL/hr; p = 
0.000 vs B2B2) and B1B2 genotypic individuals (74.53 pmol/μL/hr;             p = 0.000 vs 
B2B2) when compared to B2B2 genotypic individuals (59.10 pmol/μL/hr) . P value was 
0.000, suggesting the fact that B1B1 genotype is associated with high CETP activity and this 
high activity makes a person more susceptible to atherosclerosis. Hence B1B1 genotype and 
the resultant high CETP activity can be considered as an independent risk factor for 
atherosclerosis. Due to its intronic location this polymorphism cannot be considered as a part 
of a functional regulatory site, but can be a marker for another functional site. Its effect on 
plasma CETP mass, activity and HDL-C can be accounted by its linkage with many 5′ 
promoter region base changes like −629C>A, −971G/A and −1337C/T polymorphisms. 
Many large-scale studies have reported an association between CETP activity and the TaqIB 
polymorphism. 
  When the High Density Lipoprotein levels were compared between CETP TaqIB 
genotypes, there was a significantly low HDL level among B1B1 genotypic individuals (37.1 
mg/dL; p = 0.000 vs B2B2) and B1B2 genotypic individuals (44.6 mg/dL; p = 0.001 vs 
B2B2) when compared to B2B2 genotypic individuals (50.2 mg/dL). P value was 0.0002, 
suggesting the fact that B1B1 genotype is associated with low HDL which makes a person 
more susceptible to atherosclerosis. 
   When the Low Density Lipoprotein levels were compared between CETP TaqIB 
genotypes, there was a significantly high LDL level among B1B1 genotypic individuals 
(104.9 mg/dL; p value = 0.000 vs B2B2) and B1B2 genotype individuals (91.9 mg/dL; P = 
0.05 vs B2B2) when compared to B2B2 genotype individuals (82.3 mg/dL). P value was 
0.0004, suggesting the fact that B1B1 genotype is associated with high LDL which makes a 
person more susceptible to atherosclerosis. 
CETP activity correlated negatively with High Density Lipoprotein levels among both 
cases and controls i.e., decrease in HDL was associated with an increase in CETP activity 
among both cases and controls.  
CETP activity correlated positively with Low Density Lipoprotein levels among both 
cases and controls i.e., increase in LDL was associated with an increase in CETP activity 
among both cases and controls.  
CETP activity and the number of vessels blocked were found to be strongly positively 
correlated i.e increase in the activity is associated with an increase in the number of vessels 
blocked. So CETP activity can also be used to analyze the outcome of atherosclerotic event. 
On univariate analysis, the odds ratio for B1B1 genotype was 3.1 (95% CI – 1.8  
to 5.4) i.e., a person with B1B1 genotype is 3.1 times at a higher risk when compared to those 
with B2B2 genotype. The odds ratio for B1B2 genotype was 2.3 (95% CI – 1.3 to 3.8) i.e., a 
person with B1B2 genotype is 2.3 times at a higher risk when compared to those with B2B2 
genotype. 
On multiple logistic regression analysis, the negative correlation coefficient for HDL 
indicates that high HDL level is protective. The positive correlation coefficient for LDL, 
CETP activity and CETP B1B1 genotype indicates that high LDL, high CETP activity and 
B1B1 genotype prevalence will increase the susceptibility of atherosclerosis. The odds ratio 
on multiple logistic regression analysis was 2.04 i.e., a person with B1B1 genotype is 2.04  
times at a higher risk for atherosclerosis after all the confounding variables are matched 
 
 
  
 
 
 
 
CONCLUSION 
 
 
 
 
 
 
  
CONCLUSION 
• The results of the present study indicate significant association of Cholesteryl Ester 
Transfer Protein TaqIB polymorphism and the associated high plasma Cholesteryl 
Ester Transfer Protein activity with Coronary artery disease. 
• The Cholesteryl Ester Transfer Protein B1B1 genotype of TaqIB polymorphism and 
the high plasma Cholesteryl Ester Transfer Protein activity may be independent risk 
factors for Coronary Atherosclerosis. 
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SCOPE FOR FURTHER STUDY 
• Research aimed at identifying the strategies to inhibit Cholesteryl Ester Transfer 
Protein activity can be supported. 
• Other Cholesteryl Ester Transfer Protein gene polymorphisms may be explored to 
highlight their association with Cholesteryl Ester Transfer Protein activity and 
atherosclerosis. 
• Various transcriptional factors modulating the Cholesteryl Ester Transfer Protein gene 
expression can be studied. 
• Small interfering RNA (siRNA), based Cholesteryl Ester Transfer Protein gene 
therapy can be tried in all those who have higher Cholesteryl Ester Transfer Protein 
activity. But since atherosclerosis is a multifactorial disease, gene therapy does not 
look promising. 
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